S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion

Schlüsselwörter

biliäre Karzinome - hepatobiliäre Karzinome - Cholangiokarzinome - CCA - Diagnostik - Therapie - Risikofaktoren - Gallenblasenkarzinom - Gallengangskarzinom - cholangiozelluläres Karzinom

Publikationsverlauf

Eingereicht: 23. Januar 2023

Angenommen: 02. Februar 2023

Artikel online veröffentlicht:
11. April 2023

• Literatur

• 1 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (03) 1020-1022 https://pubmed.ncbi.nlm.nih.gov/21374666
• 2 EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64 (06) 1388-1402 https://pubmed.ncbi.nlm.nih.gov/27062661/
• 3 Frenette CT, Isaacson AJ, Bargellini I. et al. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019; 3 (03) 302-310 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713857/pdf/main.pdf
• 4 Cucchetti A, Cescon M, Erroi V. et al. Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol 2013; 27 (06) 961-972
• 5 EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236 https://www.sciencedirect.com/science/article/pii/S0168827818302150
• 6 Sangiovanni A, Prati GM, Fasani P. et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43 (06) 1303-1310 DOI: 10.1002/hep.21176.
• 7 Ioannou GN, Splan MF, Weiss NS. et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5 (08) 938-945, 945.e1-e4
• 8 Kanwal F, Kramer JR, Asch SM. et al. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology 2020; 71 (01) 44-55 DOI: 10.1002/hep.30823?download=true.
• 9 Kanwal F, Kramer JR, Mapakshi S. et al. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology 2018; 155 (06) 1828-1837.e2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279617/pdf/nihms-1504451.pdf
• 10 Brouwer WP, van der Meer AJP, Boonstra A. et al. Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. J Viral Hepat 2017; 24 (11) 1023-1031 DOI: 10.1111/jvh.12727?download=true.
• 11 Papatheodoridis G, Dalekos G, Sypsa V. et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016; 64 (04) 800-806 https://www.sciencedirect.com/science/article/pii/S0168827815007953?via%3Dihub
• 12 Papatheodoridis GV, Lampertico P, Manolakopoulos S. et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53 (02) 348-356
• 13 Yuen MF, Tanaka Y, Fong DY. et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50 (01) 80-88 https://www.sciencedirect.com/science/article/pii/S0168827808005655?via%3Dihub
• 14 Yang HI, Yuen MF, Chan HL. et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12 (06) 568-574 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70077-8/fulltext
• 15 Wong VW, Chan SL, Mo F. et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28 (10) 1660-1665
• 16 Yip TC, Wong GL, Wong VW. et al. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. J Hepatol 2020; 72 (05) 847-854 https://www.sciencedirect.com/science/article/abs/pii/S0168827819307172?via%3Dihub
• 17 Marrero JA, Kulik LM, Sirlin CB. et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68 (02) 723-750 DOI: 10.1002/hep.29913?download=true.
• 18 Mittal S, El-Serag HB, Sada YH. et al. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2016; 14 (01) 124-131.e1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690789/pdf/nihms709433.pdf
• 19 Gellert-Kristensen H, Richardson TG, Davey Smith G. et al. Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population. Hepatology 2020; 72 (03) 845-856 https://pubmed.ncbi.nlm.nih.gov/32190914
• 20 EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63 (01) 237-264
• 21 Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019; 156 (05) 1264-1281.e4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505052/pdf/nihms-1567724.pdf
• 22 Roeb E, Steffen HM, Bantel H. et al. [S2k Guideline non-alcoholic fatty liver disease]. Z Gastroenterol 2015; 53 (07) 668-723 DOI: 10.1055/s-0035-1553193.
• 23 Roeb E, Geier A. Nonalcoholic steatohepatitis (NASH) – current treatment recommendations and future developments. Z Gastroenterol 2019; 57 (04) 508-517 DOI: 10.1055/a-0784-8827.
• 24 Angulo P, Hui JM, Marchesini G. et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45 (04) 846-854 DOI: 10.1002/hep.21496?download=true.
• 25 Tanwar S, Trembling PM, Hogan BJ. et al. Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid. J Clin Gastroenterol 2017; 51 (03) 268-277 https://www.ingentaconnect.com/content/wk/jcga/2017/00000051/00000003/art00015;jsessionid=4j79pxsus6e3.x-ic-live-03
• 26 Kanwal F, Kramer J, Asch SM. et al. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology 2017; 153 (04) 996-1005.e1 https://pubmed.ncbi.nlm.nih.gov/28642197
• 27 Masuzaki R, Tateishi R, Yoshida H. et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009; 49 (06) 1954-1961 DOI: 10.1002/hep.22870.
• 28 El-Serag HB, Kanwal F, Richardson P. et al. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 2016; 64 (01) 130-137 DOI: 10.1002/hep.28535?download=true.
• 29 Ioannou GN, Beste LA, Green PK. et al. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology 2019; 157 (05) 1264-1278.e4 https://www.sciencedirect.com/science/article/abs/pii/S001650851941130X?via%3Dihub
• 30 Omata M, Cheng AL, Kokudo N. et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11 (04) 317-370 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491694/pdf/12072_2017_Article_9799.pdf
• 31 Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD?. J Hepatol 2018; 68 (02) 326-334 https://www.journal-of-hepatology.eu/article/S0168-8278(17)32353-X/fulltext
• 32 Simeone JC, Bae JP, Hoogwerf BJ. et al. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol 2017; 9: 679-688 https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1607712668_5fd3bf9ca7fc4/CLEP-144368-natural-history-of-non-alcoholic-fatty-liver-disease-----non_121317.pdf
• 33 Fujiwara N, Friedman SL, Goossens N. et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018; 68 (03) 526-549 https://www.journal-of-hepatology.eu/article/S0168-8278(17)32328-0/pdf
• 34 de Fost M, Vom Dahl S, Weverling GJ. et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 2006; 36 (01) 53-58 https://pubmed.ncbi.nlm.nih.gov/16246599
• 35 Bartlett DC, Lloyd C, McKiernan PJ. et al. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J Inherit Metab Dis 2014; 37 (05) 745-752 https://pubmed.ncbi.nlm.nih.gov/24515874
• 36 Lithner F, Wetterberg L. Hepatocellular carcinoma in patients with acute intermittent porphyria. Acta Med Scand 1984; 215 (03) 271-274 https://pubmed.ncbi.nlm.nih.gov/6328897
• 37 Baravelli CM, Sandberg S, Aarsand AK. et al. Acute hepatic porphyria and cancer risk: a nationwide cohort study. J Intern Med 2017; 282 (03) 229-240 https://pubmed.ncbi.nlm.nih.gov/28730628
• 38 Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 1993; 152 (Suppl. 01) S63-S70 https://pubmed.ncbi.nlm.nih.gov/8391447
• 39 Jang HJ, Yang HR, Ko JS. et al. Development of Hepatocellular Carcinoma in Patients with Glycogen Storage Disease: a Single Center Retrospective Study. J Korean Med Sci 2020; 35 (01) e5 https://pubmed.ncbi.nlm.nih.gov/31898434
• 40 Regenboog M, van Dussen L, Verheij J. et al. Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis 2018; 41 (05) 819-827 https://pubmed.ncbi.nlm.nih.gov/29423829
• 41 Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int 2016; 36 (09) 1239-1251 DOI: 10.1111/liv.13142?download=true.
• 42 Papatheodoridis GV, Chan HL, Hansen BE. et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015; 62 (04) 956-967 https://air.unimi.it/retrieve/handle/2434/437611/717191/1-s2.0-S0168827815000045-main.pdf
• 43 Poon D, Anderson BO, Chen LT. et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10 (11) 1111-1118
• 44 Chang MH, Chen CJ, Lai MS. et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336 (26) 1855-1859 DOI: 10.1056/NEJM199706263362602?articleTools=true.
• 45 Indolfi G, Easterbrook P, Dusheiko G. et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol 2019; 4 (06) 466-476 https://www.sciencedirect.com/science/article/abs/pii/S2468125319300421?via%3Dihub
• 46 Inoue M, Yoshimi I, Sobue T. et al. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005; 97 (04) 293-300 https://pubmed.ncbi.nlm.nih.gov/15713964
• 47 Bravi F, Tavani A, Bosetti C. et al. Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev 2017; 26 (05) 368-377
• 48 Aleksandrova K, Bamia C, Drogan D. et al. The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2015; 102 (06) 1498-1508 http://spiral.imperial.ac.uk/bitstream/10044/1/29882/11/Am%20J%20Clin%20Nutr-2015-Aleksandrova-1498-508.pdf
• 49 Setiawan VW, Wilkens LR, Lu SC. et al. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015; 148 (01) 118-125; quiz e15 https://ac.els-cdn.com/S0016508514012001/1-s2.0-S0016508514012001-main.pdf?_tid=19814e3e-2d8a-41ee-8c4e-496c2d8bda0a&acdnat=1553011004_92a7790325afb3e4f2cc4820eb51895a
• 50 Saab S, Mallam D, Cox 2nd GA. et al. Impact of coffee on liver diseases: a systematic review. Liver Int 2014; 34 (04) 495-504
• 51 Bhurwal A, Rattan P, Yoshitake S. et al. Inverse Association of Coffee with Liver Cancer Development: An Updated Systematic Review and Meta-analysis. J Gastrointestin Liver Dis 2020; 29 (03) 421-428 https://www.jgld.ro/jgld/index.php/jgld/article/download/805/1593
• 52 Kennedy OJ, Roderick P, Buchanan R. et al. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open 2017; 7 (05) e013739 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730000/pdf/bmjopen-2016-013739.pdf
• 53 Filippini T, Malavolti M, Borrelli F. et al. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev 2020; 3 (03) Cd005004
• 54 Zhang X, Harmsen WS, Mettler TA. et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 2014; 60 (06) 2008-2016 https://pubmed.ncbi.nlm.nih.gov/24798175
• 55 Singh S, Fujii LL, Murad MH. et al Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11 (12) 1573-1584.e1-e2 ; quiz e88-e89 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900882/pdf/nihms532555.pdf
• 56 Tseng CH. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver Int 2018; 38 (11) 2018-2027
• 57 Cunha V, Cotrim HP, Rocha R. et al. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review. Ann Hepatol 2020; 19 (03) 232-237
• 58 Harris K, Smith L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. Ann Pharmacother 2013; 47 (10) 1348-1352 DOI: 10.1177/1060028013503108.
• 59 Inzucchi SE, Lipska KJ, Mayo H. et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. Jama 2014; 312 (24) 2668-2675 https://jamanetwork.com/journals/jama/articlepdf/2084896/jrv140019.pdf
• 60 Vandenbulcke H, Moreno C, Colle I. et al. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study. J Hepatol 2016; 65 (03) 543-551
• 61 Ascha MS, Hanouneh IA, Lopez R. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51 (06) 1972-1978 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20209604
• 62 EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018; 69 (01) 154-181
• 63 Wang ZY, Tao QF, Wang ZH. et al. Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm – A retrospective cohort study. Am J Surg 2020; 219 (04) 717-725 https://www.sciencedirect.com/science/article/abs/pii/S000296101831609X?via%3Dihub
• 64 Jang JW, Yoo SH, Nam HC. et al. Association of Prophylactic Anti-Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy. Clin Infect Dis 2020; 71 (03) 546-555 https://pubmed.ncbi.nlm.nih.gov/31504352
• 65 Yang Y, Wen F, Li J. et al. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Int 2015; 35 (09) 2147-2154
• 66 Cabibbo G, Celsa C, Calvaruso V. et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol 2019; 71 (02) 265-273 https://www.sciencedirect.com/science/article/abs/pii/S0168827819302211?via%3Dihub
• 67 Dang H, Yeo YH, Yasuda S. et al. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. Hepatology 2020; 71 (06) 1910-1922 DOI: 10.1002/hep.30988?download=true.
• 68 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130 (07) 417-422 https://link.springer.com/content/pdf/10.1007%2Fs00432-004-0552-0.pdf
• 69 Trevisani F, Santi V, Gramenzi A. et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?. Am J Gastroenterol 2007; 102 (11) 2448-2457; quiz 2458
• 70 Trevisani F, Santi V, Gramenzi A. et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?. Am J Gastroenterol 2007; 102 (11) 2448-2457; quiz 2458
• 71 Pocha C, Dieperink E, McMaken KA. et al. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography – a randomised study. Aliment Pharmacol Ther 2013; 38 (03) 303-312 DOI: 10.1111/apt.12370.
• 72 Trinchet JC, Chaffaut C, Bourcier V. et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54 (06) 1987-1997 DOI: 10.1002/hep.24545.
• 73 Tzartzeva K, Obi J, Rich NE. et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154 (06) 1706-1718.e1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927818/pdf/nihms940431.pdf
• 74 Song BG, Sinn DH, Chi S. et al. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. Eur J Gastroenterol Hepatol 2018; 30 (12) 1447-1452
• 75 Ricco G, Cosma C, Bedogni G. et al. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. Cancer Biomark 2020; 29 (02) 189-196 https://pubmed.ncbi.nlm.nih.gov/32623383
• 76 Loglio A, Iavarone M, Facchetti F. et al. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. Liver Int 2020; 40 (08) 1987-1996 https://pubmed.ncbi.nlm.nih.gov/32301212
• 77 Poté N, Cauchy F, Albuquerque M. et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol 2015; 62 (04) 848-854 https://pubmed.ncbi.nlm.nih.gov/25450201
• 78 Xu F, Zhang L, He W. et al. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients. Dis Markers 2021; 2021: 8868370 https://pubmed.ncbi.nlm.nih.gov/33628341
• 79 Hemken PM, Sokoll LJ, Yang X. et al. Validation of a novel model for the early detection of hepatocellular carcinoma. Clin Proteomics 2019; 16: 2 https://pubmed.ncbi.nlm.nih.gov/30675135
• 80 Best J, Bechmann LP, Sowa JP. et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2020; 18 (03) 728-735.e4 https://pubmed.ncbi.nlm.nih.gov/31712073
• 81 Feng H, Li B, Li Z. et al. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer 2021; 21 (01) 401 https://pubmed.ncbi.nlm.nih.gov/33849479
• 82 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014; 11 (04) e1001624 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972088/pdf/pmed.1001624.pdf
• 83 Loomba R, Lim JK, Patton H. et al. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2020; 158 (06) 1822-1830
• 84 Petrick JL, Thistle JE, Zeleniuch-Jacquotte A. et al. Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis. Am J Gastroenterol 2018; 113 (10) 1494-1505 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521884/pdf/nihms-1027973.pdf
• 85 Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut 2020; 69 (07) 1343-1352 https://gut.bmj.com/content/69/7/1343.long
• 86 Singh S, Allen AM, Wang Z. et al Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13 (04) 643-654.e1-e9 ; quiz e39-e40 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208976/pdf/nihms-604814.pdf
• 87 Sterling RK, Lissen E, Clumeck N. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43 (06) 1317-1325
• 88 Taylor RS, Taylor RJ, Bayliss S. et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology 2020; 158 (06) 1611-1625.e12
• 89 Rockey DC, Caldwell SH, Goodman ZD. et al. Liver biopsy. Hepatology 2009; 49 (03) 1017-1044 DOI: 10.1002/hep.22742?download=true.
• 90 Silva MA, Hegab B, Hyde C. et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57 (11) 1592-1596 https://gut.bmj.com/content/gutjnl/57/11/1592.full.pdf
• 91 Müllhaupt B, Durand F, Roskams T. et al. Is tumor biopsy necessary?. Liver Transpl 2011; 17 (Suppl. 02) S14-S25 DOI: 10.1002/lt.22374?download=true.
• 92 Fuks D, Cauchy F, Fusco G. et al. Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC. J Hepatol 2014; 61 (03) 589-593
• 93 Paradis V, Fukayama M, Park YN. et al. Tumors of the liver and intrahepatic bile ducts. In: WHO Classification of Tumours Editorial Board WHO-Classification of Tumours (5th ed.) Digestive System Tumours. International Agency for Research on Cancer,. Lyon: 2019: 215-264
• 94 Terminology of nodular hepatocellular lesions. Hepatology 1995; 22 (03) 983-993 https://www.sciencedirect.com/science/article/abs/pii/0270913995903240?via%3Dihub
• 95 Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49 (02) 658-664 DOI: 10.1002/hep.22709?download=true.
• 96 Burt AD, Alves V, Bedossa P. et al. Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2018; 73 (03) 369-385 DOI: 10.1111/his.13520?download=true.
• 97 Edmondson HA, Steiner PE. Primary carcinoma of the liver. A study of 100 cases among 48900 necropsies. Cancer 1954; 7 (03) 462-503 DOI: 10.1002/1097-0142%28195405%297%3A3%3C462%3A%3AAID-CNCR2820070308%3E3.0.CO%3B2-E.
• 98 Nzeako UC, Goodman ZD, Ishak KG. Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma. Cancer 1995; 76 (04) 579-588 DOI: 10.1002/1097-0142%2819950815%2976%3A4%3C579%3A%3AAID-CNCR2820760407%3E3.0.CO%3B2-D?download=true.
• 99 Di Tommaso L, Franchi G, Park YN. et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007; 45 (03) 725-734 DOI: 10.1002/hep.21531?download=true.
• 100 Di Tommaso L, Destro A, Seok JY. et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009; 50 (04) 746-754
• 101 Lee YJ, Lee JM, Lee JS. et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015; 275 (01) 97-109
• 102 Chen N, Motosugi U, Morisaka H. et al. Added Value of a Gadoxetic Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma. Magn Reson Med Sci 2016; 15 (01) 49-59 https://www.jstage.jst.go.jp/article/mrms/15/1/15_2014-0149/_pdf
• 103 Granito A, Galassi M, Piscaglia F. et al. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 2013; 37 (03) 355-363 DOI: 10.1111/apt.12166.
• 104 Haradome H, Grazioli L, Tinti R. et al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging 2011; 34 (01) 69-78 DOI: 10.1002/jmri.22588.
• 105 Inoue T, Kudo M, Komuta M. et al. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol 2012; 47 (09) 1036-1047
• 106 Maiwald B, Lobsien D, Kahn T. et al. Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?. PLoS One 2014; 9 (11) e111935 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223069/pdf/pone.0111935.pdf
• 107 Park VY, Choi JY, Chung YE. et al. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT. Liver Int 2014; 34 (10) 1593-1602 DOI: 10.1111/liv.12550.
• 108 Sun HY, Lee JM, Shin CI. et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010; 45 (02) 96-103 https://www.ncbi.nlm.nih.gov/pubmed/20057319
• 109 Tsurusaki M, Sofue K, Isoda H. et al. Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study. J Gastroenterol 2016; 51 (01) 71-79 https://link.springer.com/content/pdf/10.1007%2Fs00535-015-1097-5.pdf
• 110 Burrel M, Llovet JM, Ayuso C. et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38 (04) 1034-1042 DOI: 10.1002/hep.1840380430.
• 111 Di Martino M, De Filippis G, De Santis A. et al. Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging. Eur Radiol 2013; 23 (04) 887-896 https://link.springer.com/content/pdf/10.1007%2Fs00330-012-2691-z.pdf
• 112 Chotipanich C, Kunawudhi A, Promteangtrong C. et al. Diagnosis of Hepatocellular Carcinoma Using C11 Choline PET/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT. Asian Pac J Cancer Prev 2016; 17 (07) 3569-3573 https://www.ncbi.nlm.nih.gov/pubmed/27510010
• 113 Hong G, Suh KS, Suh SW. et al. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol 2016; 64 (04) 852-859 https://www.ncbi.nlm.nih.gov/pubmed/26658686
• 114 Lin CY, Liao CW, Chu LY. et al. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation. Clin Nucl Med 2017; 42 (04) e183-e187 https://www.ncbi.nlm.nih.gov/pubmed/28114226
• 115 Castilla-Lievre MA, Franco D, Gervais P. et al. Diagnostic value of combining (1)C-choline and (1)(8)F-FDG PET/CT in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2016; 43 (05) 852-859 https://www.ncbi.nlm.nih.gov/pubmed/26577938
• 116 Khalili K, Kim TK, Jang HJ. et al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011; 54 (04) 723-728 https://www.sciencedirect.com/science/article/pii/S0168827810008147?via%3Dihub
• 117 Giorgio A, Montesarchio L, Gatti P. et al. Contrast-Enhanced Ultrasound: a Simple and Effective Tool in Defining a Rapid Diagnostic Work-up for Small Nodules Detected in Cirrhotic Patients during Surveillance. J Gastrointestin Liver Dis 2016; 25 (02) 205-211 https://www.ncbi.nlm.nih.gov/pubmed/27308652
• 118 Schellhaas B, Gortz RS, Pfeifer L. et al. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS. Eur J Gastroenterol Hepatol 2017; 29 (09) 1036-1044 https://www.ncbi.nlm.nih.gov/pubmed/28562394
• 119 Mitchell DG, Bruix J, Sherman M. et al. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 2015; 61 (03) 1056-1065 https://www.ncbi.nlm.nih.gov/pubmed/25041904
• 120 Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19 (03) 329-338 DOI: 10.1055/s-2007-1007122.
• 121 Chan AC, Fan ST, Poon RT. et al. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB (Oxford) 2013; 15 (06) 439-448 https://www.hpbonline.org/article/S1365-182X(15)31417-9/pdf
• 122 Chevret S, Trinchet JC, Mathieu D. et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d‘Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31 (01) 133-141 https://www.journal-of-hepatology.eu/article/S0168-8278(99)80173-1/fulltext
• 123 Johnson PJ, Berhane S, Kagebayashi C. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33 (06) 550-558 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322258/pdf/zlj550.pdf
• 124 Kitai S, Kudo M, Minami Y. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology 2008; 75 (Suppl. 01) 83-90 https://www.karger.com/Article/Abstract/173428
• 125 Leung TW, Tang AM, Zee B. et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94 (06) 1760-1769 DOI: 10.1002/cncr.10384.
• 126 Marrero JA, Fontana RJ, Barrat A. et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41 (04) 707-716 https://pubmed.ncbi.nlm.nih.gov/15795889
• 127 Pinato DJ, Sharma R, Allara E. et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol 2017; 66 (02) 338-346 https://www.journal-of-hepatology.eu/article/S0168-8278(16)30535-9/pdf
• 128 Vitale A, Saracino E, Boccagni P. et al. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplant Proc 2009; 41 (04) 1260-1263 https://www.sciencedirect.com/science/article/pii/S0041134509004850?via%3Dihub
• 129 Yau T, Tang VY, Yao TJ. et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146 (07) 1691-700.e3 https://www.gastrojournal.org/article/S0016-5085(14)00243-1/pdf
• 130 Sohn JH, Duran R, Zhao Y. et al. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clin Gastroenterol Hepatol 2017; 15 (05) 746-755.e4 https://www.cghjournal.org/article/S1542-3565(16)31049-7/pdf
• 131 Yang A, Ju W, Yuan X. et al. Comparison between liver resection and liver transplantation on outcomes in patients with solitary hepatocellular carcinoma meeting UNOS criteria: a population-based study of the SEER database. Oncotarget 2017; 8 (57) 97428-97438 https://www.oncotarget.com/article/22134/pdf
• 132 Krenzien F, Schmelzle M, Struecker B. et al. Liver Transplantation and Liver Resection for Cirrhotic Patients with Hepatocellular Carcinoma: Comparison of Long-Term Survivals. J Gastrointest Surg 2018; 22 (05) 840-848 DOI: 10.1007/s11605-018-3690-4.
• 133 Cherqui D, Laurent A, Mocellin N. et al. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 2009; 250 (05) 738-746
• 134 Eguchi S, Kanematsu T, Arii S. et al. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 2011; 98 (04) 552-557 DOI: 10.1002/bjs.7393?download=true.
• 135 Sapisochin G, Goldaracena N, Laurence JM. et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology 2016; 64 (06) 2077-2088 DOI: 10.1002/hep.28643.
• 136 Mazzaferro V, Battiston C, Sposito C. Pro (With Caution): Extended oncologic indications in liver transplantation. Liver Transpl 2018; 24 (01) 98-103 DOI: 10.1002/lt.24963.
• 137 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699 DOI: 10.1056/NEJM199603143341104?articleTools=true.
• 138 Agopian VG, Harlander-Locke MP, Ruiz RM. et al. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. Ann Surg 2017; 266 (03) 525-535
• 139 Bundesärztekammer, Richtlinien zur Organtransplantation gem. § 16 TPG. Deutsches Ärzteblatt 2019; DOI: 10.3238/arztebl.2019.rili_baek_OrgaWlOvLeberTx2019092.
• 140 von Felden J, Villanueva A. Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2020; 26 (06) 823-831
• 141 Yao FY, Ferrell L, Bass NM. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33 (06) 1394-1403
• 142 Mazzaferro V, Llovet JM, Miceli R. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10 (01) 35-43 https://www.sciencedirect.com/science/article/pii/S1470204508702845?via%3Dihub
• 143 Sinha J, Mehta N, Dodge JL. et al. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol. Hepatology 2019; 70 (04) 1185-1196 DOI: 10.1002/hep.30570.
• 144 Lai Q, Vitale A, Halazun K. et al. Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. Cancers (Basel) 2020; 12 (02) DOI: 10.3390/cancers12020452. https://res.mdpi.com/d_attachment/cancers/cancers-12-00452/article_deploy/cancers-12-00452-v2.pdf
• 145 Mehta N, Guy J, Frenette CT. et al. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol 2018; 16 (06) 955-964 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053266/pdf/nihms922574.pdf
• 146 Otto G, Herber S, Heise M. et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12 (08) 1260-1267 DOI: 10.1002/lt.20837?download=true.
• 147 Di Sandro S, Sposito C, Lauterio A. et al. Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients. J Am Coll Surg 2018; 226 (06) 1147-1159 https://www.sciencedirect.com/science/article/abs/pii/S1072751518302199?via%3Dihub
• 148 Ferrer-Fàbrega J, Forner A, Liccioni A. et al. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology 2016; 63 (03) 839-849 DOI: 10.1002/hep.28339?download=true.
• 149 Scatton O, Goumard C, Cauchy F. et al. Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation. J Surg Oncol 2015; 111 (08) 1007-1015 DOI: 10.1002/jso.23916?download=true.
• 150 de Haas RJ, Lim C, Bhangui P. et al. Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: An intention-to-treat analysis. Hepatology 2018; 67 (01) 204-215 DOI: 10.1002/hep.29468?download=true.
• 151 Bhangui P, Allard MA, Vibert E. et al. Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes?. Ann Surg 2016; 264 (01) 155-163 https://www.ingentaconnect.com/content/wk/sla/2016/00000264/00000001/art00029;jsessionid=5ees0b4oapp5t.x-ic-live-02
• 152 Pichlmayr R. Is there a place for liver grafting for malignancy?. Transplant Proc 1988; 20 (01) 478-482
• 153 Roayaie S, Schwartz JD, Sung MW. et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10 (04) 534-540 DOI: 10.1002/lt.20128?download=true.
• 154 Shetty K, Timmins K, Brensinger C. et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10 (07) 911-918 DOI: 10.1002/lt.20140?download=true.
• 155 Lee HW, Song GW, Lee SG. et al. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma. Liver Transpl 2018; 24 (09) 1243-1251 DOI: 10.1002/lt.25056.
• 156 Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl 2013; 19 (06) 634-645 DOI: 10.1002/lt.23652.
• 157 Vibert E, Azoulay D, Hoti E. et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10 (01) 129-137 DOI: 10.1111/j.1600-6143.2009.02750.x.
• 158 Yao FY, Mehta N, Flemming J. et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61 (06) 1968-1977 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809192/pdf/nihms667031.pdf
• 159 Hameed B, Mehta N, Sapisochin G. et al. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl 2014; 20 (08) 945-951 DOI: 10.1002/lt.23904?download=true.
• 160 Heimbach JK, Kulik LM, Finn RS. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67 (01) 358-380 DOI: 10.1002/hep.29086.
• 161 Mehta N, Dodge JL, Roberts JP. et al. Alpha-Fetoprotein Decrease from > 1000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology 2019; 69 (03) 1193-1205 DOI: 10.1002/hep.30413?download=true.
• 162 EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 2016; 64 (02) 433-485
• 163 Martin P, DiMartini A, Feng S. et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59 (03) 1144-1165 DOI: 10.1002/hep.26972?download=true.
• 164 Adani GL, Baccarani U, Lorenzin D. et al. Elderly versus young liver transplant recipients: patient and graft survival. Transplant Proc 2009; 41 (04) 1293-1294
• 165 Cross TJ, Antoniades CG, Muiesan P. et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 2007; 13 (10) 1382-1388 DOI: 10.1002/lt.21181?download=true.
• 166 Grąt M, Kornasiewicz O, Grąt K. et al. Short and long-term outcomes after primary liver transplantation in elderly patients. Pol Przegl Chir 2013; 85 (10) 581-588
• 167 Aduen JF, Sujay B, Dickson RC. et al. Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years. Mayo Clin Proc 2009; 84 (11) 973-978 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770908/pdf/mayoclinproc_84_11_004.pdf
• 168 Lipshutz GS, Hiatt J, Ghobrial RM. et al Outcome of liver transplantation in septuagenarians: a single-center experience. Arch Surg 2007; 142 (08) 775-781 ; discussion 781-784 https://jamanetwork.com/journals/jamasurgery/articlepdf/400501/spc70006_775_784.pdf
• 169 Oezcelik A, Dayangac M, Guler N. et al. Living Donor Liver Transplantation in Patients 70 Years or Older. Transplantation 2015; 99 (07) 1436-1440
• 170 Taner CB, Ung RL, Rosser BG. et al. Age is not a contraindication for orthotopic liver transplantation: a single institution experience with recipients older than 75 years. Hepatol Int 2012; 6 (01) 403-407 DOI: 10.1007/s12072-011-9286-7.
• 171 Huang X, Lu S. Impact of preoperative locoregional therapy on recurrence and patient survival following liver transplantation for hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol 2017; 52 (02) 143-149 DOI: 10.1080/00365521.2016.1236396.
• 172 Kulik L, Heimbach JK, Zaiem F. et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology 2018; 67 (01) 381-400 DOI: 10.1002/hep.29485.
• 173 Sneiders D, Houwen T, Pengel LHM. et al. Systematic Review and Meta-Analysis of Posttransplant Hepatic Artery and Biliary Complications in Patients Treated With Transarterial Chemoembolization Before Liver Transplantation. Transplantation 2018; 102 (01) 88-96
• 174 Clavien PA, Lesurtel M, Bossuyt PM. et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13 (01) e11-e22 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417764/pdf/nihms392425.pdf
• 175 Beal EW, Dittmar KM, Hanje AJ. et al. Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall Survival. Front Oncol 2016; 6: 143
• 176 Cascales-Campos P, Martinez-Insfran LA, Ramirez P. et al. Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It?. Transplant Proc 2018; 50 (02) 591-594 https://www.sciencedirect.com/science/article/abs/pii/S0041134517309284
• 177 Finkenstedt A, Vikoler A, Portenkirchner M. et al. Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. Liver Int 2016; 36 (05) 688-695 DOI: 10.1111/liv.12966.
• 178 Györi GP, Felsenreich DM, Silberhumer GR. et al. Multimodality locoregional treatment strategies for bridging HCC patients before liver transplantation. Eur Surg 2017; 49 (05) 236-243 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653748/pdf/10353_2017_Article_487.pdf
• 179 Jianyong L, Jinjing Z, Lunan Y. et al. Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma. Sci Rep 2017; 7: 41624 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290748/pdf/srep41624.pdf
• 180 Nicolini D, Agostini A, Montalti R. et al. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World J Gastroenterol 2017; 23 (20) 3690-3701 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449426/pdf/WJG-23-3690.pdf
• 181 Gabr A, Abouchaleh N, Ali R. et al. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. Eur J Radiol 2017; 93: 100-106 https://www.sciencedirect.com/science/article/abs/pii/S0720048X17302012
• 182 Lai Q, Vitale A, Iesari S. et al. The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation. Liver Transpl 2019; 25 (07) 1023-1033 DOI: 10.1002/lt.25492?download=true.
• 183 Oligane HC, Xing M, Kim HS. Effect of Bridging Local-Regional Therapy on Recurrence of Hepatocellular Carcinoma and Survival after Orthotopic Liver Transplantation. Radiology 2017; 282 (03) 869-879
• 184 Millonig G, Graziadei IW, Freund MC. et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13 (02) 272-279 DOI: 10.1002/lt.21033?download=true.
• 185 Cucchetti A, Cescon M, Bigonzi E. et al. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl 2011; 17 (11) 1344-1354 DOI: 10.1002/lt.22397?download=true.
• 186 Lai Q, Avolio AW, Graziadei I. et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013; 19 (10) 1108-1118 DOI: 10.1002/lt.23706?download=true.
• 187 Kim DJ, Clark PJ, Heimbach J. et al. Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. Am J Transplant 2014; 14 (06) 1383-1390 DOI: 10.1111/ajt.12684?download=true.
• 188 Riaz A, Miller FH, Kulik LM. et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. Jama 2010; 303 (11) 1062-1069 https://jamanetwork.com/journals/jama/articlepdf/185545/joc05021_1062_1069.pdf
• 189 O‘Connor JK, Trotter J, Davis GL. et al. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012; 18 (08) 949-954 DOI: 10.1002/lt.23439?download=true.
• 190 Facciuto ME, Singh MK, Rochon C. et al. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol 2012; 105 (07) 692-698 DOI: 10.1002/jso.22104?download=true.
• 191 Sapisochin G, Barry A, Doherty M. et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017; 67 (01) 92-99
• 192 Degroote H, Callebout E, Iesari S. et al. Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium. Surg Oncol 2019; DOI: 10.1016/j.suronc.2019.10.006. https://pubmed.ncbi.nlm.nih.gov/31630912
• 193 Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl 2015; 21 (09) 1142-1152 https://deepblue.lib.umich.edu/bitstream/handle/2027.42/113108/lt24169.pdf?sequence=1
• 194 Chapman WC, Garcia-Aroz S, Vachharajani N. et al. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions. J Am Coll Surg 2017; 224 (04) 610-621 https://www.sciencedirect.com/science/article/abs/pii/S1072751516317240
• 195 Graziadei I, Zoller H, Fickert P. et al. Indications for liver transplantation in adults: Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). Wien Klin Wochenschr 2016; 128 (19) 679-690 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052293/pdf/508_2016_Article_1046.pdf
• 196 Mazzaferro V, Sposito C, Zhou J. et al. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology 2018; 154 (01) 128-139 https://www.gastrojournal.org/article/S0016-5085(17)36184-X/fulltext
• 197 Halazun KJ, Tabrizian P, Najjar M. et al. Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies. Ann Surg 2018; 268 (04) 690-699
• 198 Hong SK, Lee KW, Kim HS. et al. Living donor liver transplantation for hepatocellular carcinoma in Seoul National University. Hepatobiliary Surg Nutr 2016; 5 (06) 453-460
• 199 Kornberg A, Schernhammer M, Friess H. (18)F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017; 5 (03) 224-234
• 200 Assalino M, Terraz S, Grat M. et al. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion – a multi-center retrospective cohort study. Transpl Int 2020; 33 (05) 567-575
• 201 Parikh ND, Yopp A, Singal AG. Controversies in criteria for liver transplantation in hepatocellular carcinoma. Curr Opin Gastroenterol 2016; 32 (03) 182-188
• 202 Salem R, Gordon AC, Mouli S. et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology 2016; 151 (06) 1155-1163.e2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124387/pdf/nihms813288.pdf
• 203 Ettorre GM, Levi Sandri GB, Laurenzi A. et al. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World J Surg 2017; 41 (01) 241-249 DOI: 10.1007/s00268-016-3682-z.
• 204 Schwacha-Eipper B, Minciuna I, Banz V. et al. Immunotherapy as a downstaging therapy for liver transplantation. Hepatology 2020; DOI: 10.1002/hep.31234.
• 205 Golse N, Radenne S, Rode A. et al. Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review. Exp Clin Transplant 2018; 16 (02) 227-236
• 206 Hoffmann K, Ganten T, Gotthardtp D. et al. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients – a prospective, randomized, double-blind, phase III trial. BMC Cancer 2015; 15: 392 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449604/pdf/12885_2015_Article_1373.pdf
• 207 Berenguer M, Burra P, Ghobrial M. et al. Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 2020; 104 (06) 1143-1149
• 208 Verna EC, Patel YA, Aggarwal A. et al. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020; 20 (02) 333-347 DOI: 10.1111/ajt.15697?download=true.
• 209 Vivarelli M, Cucchetti A, Piscaglia F. et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11 (05) 497-503 DOI: 10.1002/lt.20391?download=true.
• 210 Vivarelli M, Cucchetti A, La Barba G. et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248 (05) 857-862
• 211 Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC. et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013; 59 (06) 1193-1199
• 212 Decaens T, Roudot-Thoraval F, Bresson-Hadni S. et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006; 12 (45) 7319-7325 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087490/pdf/WJG-12-7319.pdf
• 213 Tan PS, Muthiah MD, Koh T. et al. Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation. Transplantation 2019; 103 (03) 470-480
• 214 Duvoux C, Toso C. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?. Transplant Rev (Orlando) 2015; 29 (03) 168-174
• 215 Tarantino G, Magistri P, Ballarin R. et al. Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature. Front Pharmacol 2016; 7: 387 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073152/pdf/fphar-07-00387.pdf
• 216 Teperman L, Moonka D, Sebastian A. et al. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl 2013; 19 (07) 675-689 DOI: 10.1002/lt.23658?download=true.
• 217 De Simone P, Metselaar HJ, Fischer L. et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009; 15 (10) 1262-1269 DOI: 10.1002/lt.21827?download=true.
• 218 Fischer L, Saliba F, Kaiser GM. et al. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. Transplantation 2015; 99 (07) 1455-1462
• 219 Geissler EK, Schnitzbauer AA, Zülke C. et al. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation 2016; 100 (01) 116-125
• 220 Trevisani F, Frigerio M, Santi V. et al. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010; 42 (05) 341-347
• 221 Paradis V, Zalinski S, Chelbi E. et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49 (03) 851-859 DOI: 10.1002/hep.22734.
• 222 Piscaglia F, Svegliati-Baroni G, Barchetti A. et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 2016; 63 (03) 827-838 DOI: 10.1002/hep.28368.
• 223 Ertle J, Dechêne A, Sowa JP. et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128 (10) 2436-2443 DOI: 10.1002/ijc.25797?download=true.
• 224 Zhou Y, Lei X, Wu L. et al. Outcomes of hepatectomy for noncirrhotic hepatocellular carcinoma: a systematic review. Surg Oncol 2014; 23 (04) 236-242
• 225 Faber W, Sharafi S, Stockmann M. et al. Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver. Surgery 2013; 153 (04) 510-517
• 226 Cauchy F, Zalinski S, Dokmak S. et al. Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg 2013; 100 (01) 113-121 DOI: 10.1002/bjs.8963?download=true.
• 227 Dasari BV, Kamarajah SK, Hodson J. et al. Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver. HPB (Oxford) 2020; 22 (03) 383-390 https://www.sciencedirect.com/science/article/abs/pii/S1365182X19306215?via%3Dihub
• 228 Ju M, Yopp AC. The Utility of Anatomical Liver Resection in Hepatocellular Carcinoma: Associated with Improved Outcomes or Lack of Supportive Evidence?. Cancers (Basel) 2019; 11 (10) DOI: 10.3390/cancers11101441. https://res.mdpi.com/d_attachment/cancers/cancers-11-01441/article_deploy/cancers-11-01441.pdf
• 229 Moris D, Tsilimigras DI, Kostakis ID. et al. Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis. Eur J Surg Oncol 2018; 44 (07) 927-938 https://www.sciencedirect.com/science/article/abs/pii/S0748798318310242?via%3Dihub
• 230 Arnaoutakis DJ, Mavros MN, Shen F. et al. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Ann Surg Oncol 2014; 21 (01) 147-154 DOI: 10.1245/s10434-013-3211-3.
• 231 Lang H, Sotiropoulos GC, Brokalaki EI. et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 2007; 205 (01) 27-36
• 232 Bège T, Le Treut YP, Hardwigsen J. et al. Prognostic factors after resection for hepatocellular carcinoma in nonfibrotic or moderately fibrotic liver. A 116-case European series. J Gastrointest Surg 2007; 11 (05) 619-625 DOI: 10.1007/s11605-006-0023-9.
• 233 Teegen EM, Mogl MT, Pratschke J. et al. Adrenal Metastasis of Hepatocellular Carcinoma in Patients following Liver Resection or Liver Transplantation: Experience from a Tertiary Referral Center. Int J Surg Oncol 2018; 2018: 4195076 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087597/pdf/IJSO2018-4195076.pdf
• 234 Wang YY, Zhao XH, Ma L. et al. Comparison of the ability of Child-Pugh score, MELD score, and ICG-R15 to assess preoperative hepatic functional reserve in patients with hepatocellular carcinoma. J Surg Oncol 2018; 118 (03) 440-445 DOI: 10.1002/jso.25184?download=true.
• 235 Rubin TM, Heyne K, Luchterhand A. et al. Kinetic validation of the LiMAx test during 10000 intravenous (13)C-methacetin breath tests. J Breath Res 2017; 12 (01) 016005 DOI: 10.1088/1752-7163/aa820b.
• 236 Stockmann M, Lock JF, Riecke B. et al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 2009; 250 (01) 119-125
• 237 Huang Z, Huang J, Zhou T. et al. Prognostic value of liver stiffness measurement for the liver-related surgical outcomes of patients under hepatic resection: A meta-analysis. PLoS One 2018; 13 (01) e0190512 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764309/pdf/pone.0190512.pdf
• 238 Simonetto DA, Liu M, Kamath PS. Portal Hypertension and Related Complications: Diagnosis and Management. Mayo Clin Proc 2019; 94 (04) 714-726 https://www.sciencedirect.com/science/article/abs/pii/S0025619618310085?via%3Dihub
• 239 Roayaie S, Jibara G, Tabrizian P. et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 2015; 62 (02) 440-451 DOI: 10.1002/hep.27745.
• 240 Ishizawa T, Hasegawa K, Aoki T. et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134 (07) 1908-1916 https://www.sciencedirect.com/science/article/pii/S0016508508004277?via%3Dihub
• 241 Torzilli G, Belghiti J, Kokudo N. et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg 2013; 257 (05) 929-937
• 242 Koh YX, Tan HL, Lye WK. et al. Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence. World J Hepatol 2018; 10 (06) 433-447 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033716/pdf/WJH-10-433.pdf
• 243 Zaydfudim VM, Vachharajani N, Klintmalm GB. et al. Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria. Ann Surg 2016; 264 (04) 650-658 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279918/pdf/nihms-835604.pdf
• 244 Tsilimigras DI, Bagante F, Moris D. et al. Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol 2020; 27 (07) 2321-2331 DOI: 10.1245/s10434-020-08452-3.
• 245 Pang TC, Lam VW. Surgical management of hepatocellular carcinoma. World J Hepatol 2015; 7 (02) 245-252 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342606/pdf/WJH-7-245.pdf
• 246 Feng X, Su Y, Zheng S. et al. A double blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence. HPB (Oxford) 2017; 19 (08) 667-674
• 247 Wakabayashi G, Cherqui D, Geller DA. et al. Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg 2015; 261 (04) 619-629
• 248 Cherqui D, Soubrane O. Laparoscopic Liver Resection: An Ongoing Revolution. Ann Surg 2017; 265 (05) 864-865 https://www.ingentaconnect.com/content/wk/sla/2017/00000265/00000005/art00019
• 249 Andreou A, Struecker B, Raschzok N. et al. Minimal-invasive versus open hepatectomy for hepatocellular carcinoma: Comparison of postoperative outcomes and long-term survivals using propensity score matching analysis. Surg Oncol 2018; 27 (04) 751-758 https://www.sciencedirect.com/science/article/abs/pii/S0960740418302512?via%3Dihub
• 250 Haber PK, Wabitsch S, Krenzien F. et al. Laparoscopic liver surgery in cirrhosis – Addressing lesions in posterosuperior segments. Surg Oncol 2019; 28: 140-144 https://www.sciencedirect.com/science/article/abs/pii/S0960740418304614?via%3Dihub
• 251 Levi Sandri GB, Ettorre GM, Aldrighetti L. et al. Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry. Surg Endosc 2019; 33 (05) 1451-1458 DOI: 10.1007/s00464-018-6426-3.
• 252 Felli E, Cillo U, Pinna AD. et al. Salvage liver transplantation after laparoscopic resection for hepatocellular carcinoma: a multicenter experience. Updates Surg 2015; 67 (02) 215-222 DOI: 10.1007/s13304-015-0323-2.
• 253 Bruix J, Takayama T, Mazzaferro V. et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16 (13) 1344-1354 https://www.sciencedirect.com/science/article/pii/S1470204515001989?via%3Dihub
• 254 Lee JH, Lee JH, Lim YS. et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015; 148 (07) 1383-1391.e6 https://www.sciencedirect.com/science/article/pii/S0016508515003054?via%3Dihub
• 255 Mazzaferro V, Romito R, Schiavo M. et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44 (06) 1543-1554 DOI: 10.1002/hep.21415.
• 256 Samuel M, Chow PK, Chan Shih-Yen E. et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009; Cd001199
• 257 Takayama T, Sekine T, Makuuchi M. et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-807 https://www.sciencedirect.com/science/article/pii/S0140673600026544?via%3Dihub
• 258 Chen MS, Li JQ, Zheng Y. et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243 (03) 321-328 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1448947/pdf/20060300s00006p321.pdf
• 259 Feng K, Yan J, Li X. et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57 (04) 794-802 https://www.sciencedirect.com/science/article/pii/S0168827812003613?via%3Dihub
• 260 Huang J, Yan L, Cheng Z. et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252 (06) 903-912
• 261 Ng KKC, Chok KSH, Chan ACY. et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg 2017; 104 (13) 1775-1784 DOI: 10.1002/bjs.10677.
• 262 Yin L, Li H, Li AJ. et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol 2014; 61 (01) 82-88 https://www.sciencedirect.com/science/article/pii/S0168827814001561?via%3Dihub
• 263 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (01) 52-60 DOI: 10.1055/s-0030-1247132.
• 264 Wahab MA, Shehta A, Hamed H. et al. Predictors of recurrence in hepatitis C virus related hepatocellular carcinoma after hepatic resection: a retrospective cohort study. Eurasian J Med 2014; 46 (01) 36-41 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261437/pdf/eajm-46-1-36.pdf
• 265 Ramacciato G, Mercantini P, Nigri GR. et al. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology 2006; 53 (72) 898-903
• 266 Di Costanzo GG, Tortora R, D‘Adamo G. et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. J Gastroenterol Hepatol 2015; 30 (03) 559-565 DOI: 10.1111/jgh.12791.
• 267 Cucchetti A, Piscaglia F, Cescon M. et al. An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Dig Liver Dis 2014; 46 (03) 257-263
• 268 Nishikawa H, Inuzuka T, Takeda H. et al. Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol 2011; 11: 143 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260104/pdf/1471-230X-11-143.pdf
• 269 Uhlig J, Sellers CM, Stein SM. et al. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. Eur Radiol 2019; 29 (05) 2679-2689 DOI: 10.1007/s00330-018-5902-4.
• 270 Salmi A, Turrini R, Lanzani G. et al. Radiofrequency ablation of hepatocellular carcinoma in patients with and without cirrhosis. J Ultrasound 2009; 12 (03) 118-124 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552707/pdf/main.pdf
• 271 Mohanty S, Rajaram R, Bilimoria KY. et al. Assessment of non-surgical versus surgical therapy for localized hepatocellular carcinoma. J Surg Oncol 2016; 113 (02) 175-180 DOI: 10.1002/jso.24113.
• 272 Yamauchi R, Takata K, Shinagawa Y. et al. Hepatocellular Carcinoma Arising in a Non-cirrhotic Liver with Secondary Hemochromatosis. Intern Med 2019; 58 (05) 661-665 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443541/pdf/1349-7235-58-0661.pdf
• 273 Livraghi T, Goldberg SN, Lazzaroni S. et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210 (03) 655-661
• 274 Lencioni RA, Allgaier HP, Cioni D. et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228 (01) 235-240
• 275 Lin SM, Lin CJ, Lin CC. et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004; 127 (06) 1714-1723 https://www.sciencedirect.com/science/article/abs/pii/S0016508504015720?via%3Dihub
• 276 Bruix J, Sherman M, Llovet JM. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35 (03) 421-430
• 277 Shiina S, Teratani T, Obi S. et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129 (01) 122-130 https://www.sciencedirect.com/science/article/abs/pii/S0016508505006918?via%3Dihub
• 278 Brunello F, Veltri A, Carucci P. et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol 2008; 43 (06) 727-735 DOI: 10.1080/00365520701885481?needAccess=true.
• 279 Lin SM, Lin CJ, Lin CC. et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54 (08) 1151-1156 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774888/pdf/gut05401151.pdf
• 280 Shiina S, Teratani T, Obi S. et al. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002; 62 (Suppl. 01) 64-68 https://www.karger.com/Article/Pdf/48278
• 281 Hara K, Takeda A, Tsurugai Y. et al. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis. Hepatology 2019; 69 (06) 2533-2545 DOI: 10.1002/hep.30591?download=true.
• 282 Peng ZW, Zhang YJ, Chen MS. et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31 (04) 426-432
• 283 Liu H, Wang ZG, Fu SY. et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg 2016; 103 (04) 348-356 DOI: 10.1002/bjs.10061.
• 284 Endo K, Kuroda H, Oikawa T. et al. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. Scand J Gastroenterol 2018; 53 (12) 1575-1583 DOI: 10.1080/00365521.2018.1548645.
• 285 Fukutomi S, Nomura Y, Nakashima O. et al. Evaluation of hepatocellular carcinoma spread via the portal system by 3-dimensional mapping. HPB (Oxford) 2017; 19 (12) 1119-1125
• 286 Smolock AR, Cristescu MM, Hinshaw A. et al. Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone. Abdom Radiol (NY) 2018; 43 (09) 2497-2504 DOI: 10.1007/s00261-018-1464-9.
• 287 Bonomo G, Della Vigna P, Monfardini L. et al. Combined therapies for the treatment of technically unresectable liver malignancies: bland embolization and radiofrequency thermal ablation within the same session. Cardiovasc Intervent Radiol 2012; 35 (06) 1372-1379 DOI: 10.1007/s00270-012-0341-0.
• 288 Lo CM, Ngan H, Tso WK. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35 (05) 1164-1171 DOI: 10.1053/jhep.2002.33156.
• 289 Lammer J, Malagari K, Vogl T. et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (01) 41-52 https://www.zora.uzh.ch/id/eprint/24207/1/Lammer_CardiovascInterventRadiol_2010_V.pdf
• 290 Golfieri R, Giampalma E, Renzulli M. et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111 (02) 255-264 https://iris.unito.it/retrieve/handle/2318/149077/25760/art%20Doxorubicina-Tace%202014.pdf
• 291 Yamada R, Bassaco B, Bracewell S. et al. Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC). J Gastrointest Oncol 2019; 10 (02) 348-353
• 292 Llovet JM, Real MI, Montana X. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739 https://www.sciencedirect.com/science/article/pii/S014067360208649X?via%3Dihub
• 293 Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020; 1 (01) Cd011313
• 294 Yang J, Wang J, Zhou H. et al. Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial. Endoscopy 2018; 50 (08) 751-760 DOI: 10.1055/s-0043-124870.
• 295 Ludwig JM, Zhang D, Xing M. et al. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus (90)Y-radioembolization for hepatocellular carcinoma. Eur Radiol 2017; 27 (05) 2031-2041 https://link.springer.com/content/pdf/10.1007%2Fs00330-016-4548-3.pdf
• 296 Casadei Gardini A, Tamburini E, Inarrairaegui M. et al. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther 2018; 11: 7315-7321 https://www.dovepress.com/getfile.php?fileID=45631
• 297 Levillain H, Bagni O, Deroose CM. et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging 2021; 48 (05) 1570-1584 https://pubmed.ncbi.nlm.nih.gov/33433699
• 298 Garin E, Tselikas L, Guiu B. et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6 (01) 17-29 https://pubmed.ncbi.nlm.nih.gov/33166497
• 299 Salem R, Johnson GE, Kim E. et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology 2021; 74 (05) 2342-2352 https://pubmed.ncbi.nlm.nih.gov/33739462
• 300 Salem R, Padia SA, Lam M. et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 2019; 46 (08) 1695-1704 https://pubmed.ncbi.nlm.nih.gov/31098749
• 301 Kolligs FT, Bilbao JI, Jakobs T. et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int 2015; 35 (06) 1715-1721 DOI: 10.1111/liv.12750?download=true.
• 302 Katsanos K, Kitrou P, Spiliopoulos S. et al. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One 2017; 12 (09) e0184597 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608206/pdf/pone.0184597.pdf
• 303 Pitton MB, Kloeckner R, Ruckes C. et al. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2015; 38 (02) 352-360 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355443/pdf/270_2014_Article_1012.pdf
• 304 Lobo L, Yakoub D, Picado O. et al. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol 2016; 39 (11) 1580-1588 DOI: 10.1007/s00270-016-1426-y.
• 305 Salem R, Gilbertsen M, Butt Z. et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013; 11 (10) 1358-1365.e1 https://www.sciencedirect.com/science/article/abs/pii/S1542356513005971?via%3Dihub
• 306 Sangro B, Maini CL, Ettorre GM. et al. Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. Eur J Nucl Med Mol Imaging 2018; 45 (10) 1721-1730 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097757/pdf/259_2018_Article_3968.pdf
• 307 Johnson GE, Monsky WL, Valji K. et al. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol 2016; 27 (08) 1123-1129
• 308 Hilgard P, Hamami M, Fouly AE. et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52 (05) 1741-1749 DOI: 10.1002/hep.23944?download=true.
• 309 Sangro B, Carpanese L, Cianni R. et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54 (03) 868-878 DOI: 10.1002/hep.24451?download=true.
• 310 Kulik LM, Carr BI, Mulcahy MF. et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47 (01) 71-81 DOI: 10.1002/hep.21980?download=true.
• 311 Mazzaferro V, Sposito C, Bhoori S. et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013; 57 (05) 1826-1837 DOI: 10.1002/hep.26014?download=true.
• 312 Salem R, Lewandowski RJ, Mulcahy MF. et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138 (01) 52-64
• 313 Rim CH, Kim CY, Yang DS. et al. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiother Oncol 2018; 129 (01) 112-122 https://www.sciencedirect.com/science/article/abs/pii/S0167814017327305?via%3Dihub
• 314 Vilgrain V, Pereira H, Assenat E. et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. The Lancet Oncology 2017; 18 (12) 1624-1636
• 315 Chow PKH, Gandhi M, Tan SB. et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 2018; 36 (19) 1913-1921 https://www.ncbi.nlm.nih.gov/pubmed/29498924
• 316 Vogel A, Cervantes A, Chau I. et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl. 04) iv238-iv255
• 317 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019; 13 (03) 227-299 DOI: 10.5009/gnl19024.
• 318 Feng M, Suresh K, Schipper MJ. et al. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. JAMA Oncol 2018; 4 (01) 40-47 https://jamanetwork.com/journals/jamaoncology/articlepdf/2648321/jamaoncology_feng_2017_oi_170051.pdf
• 319 Kim JW, Kim DY, Han KH. et al. Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma. Dig Liver Dis 2019; 51 (03) 445-451 https://www.sciencedirect.com/science/article/abs/pii/S1590865818312234?via%3Dihub
• 320 Moon DH, Wang AZ, Tepper JE. A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy. Radiother Oncol 2018; 126 (03) 527-533 https://www.sciencedirect.com/science/article/abs/pii/S0167814018300203?via%3Dihub
• 321 Takeda A, Sanuki N, Tsurugai Y. et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer 2016; 122 (13) 2041-2049 DOI: 10.1002/cncr.30008?download=true.
• 322 Lasley FD, Mannina EM, Johnson CS. et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol 2015; 5 (05) e443-e449 https://www.sciencedirect.com/science/article/abs/pii/S1879850015000703?via%3Dihub
• 323 Scorsetti M, Comito T, Cozzi L. et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol 2015; 141 (07) 1301-1309 DOI: 10.1007/s00432-015-1929-y.
• 324 Bujold A, Massey CA, Kim JJ. et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013; 31 (13) 1631-1639
• 325 Méndez Romero A, Wunderink W, Hussain SM. et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 2006; 45 (07) 831-837 DOI: 10.1080/02841860600897934?needAccess=true.
• 326 Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiother Oncol 2019; 131: 135-144 https://www.sciencedirect.com/science/article/abs/pii/S0167814018336260?via%3Dihub
• 327 Lee J, Shin IS, Yoon WS. et al. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review. Radiother Oncol 2020; 145: 63-70 https://www.sciencedirect.com/science/article/abs/pii/S0167814019335042?via%3Dihub
• 328 Rajyaguru DJ, Borgert AJ, Smith AL. et al. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database. J Clin Oncol 2018; 36 (06) 600-608
• 329 Wahl DR, Stenmark MH, Tao Y. et al. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol 2016; 34 (05) 452-459 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872011/pdf/JCO614925.pdf
• 330 Sapir E, Tao Y, Schipper MJ. et al. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2018; 100 (01) 122-130 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818982/pdf/nihms942371.pdf
• 331 Mohnike K, Steffen IG, Seidensticker M. et al. Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial. Cardiovasc Intervent Radiol 2019; 42 (02) 239-249 DOI: 10.1007/s00270-018-2127-5.
• 332 Collettini F, Schreiber N, Schnapauff D. et al. CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma. Strahlenther Onkol 2015; 191 (05) 405-412 DOI: 10.1007/s00066-014-0781-3.
• 333 Mohnike K, Wieners G, Schwartz F. et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 2010; 78 (01) 172-179
• 334 Fukumitsu N, Sugahara S, Nakayama H. et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009; 74 (03) 831-836
• 335 Bush DA, Smith JC, Slater JD. et al. Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis. Int J Radiat Oncol Biol Phys 2016; 95 (01) 477-482
• 336 Kim TH, Park JW, Kim YJ. et al. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat 2015; 47 (01) 34-45 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296848/pdf/crt-2013-218.pdf
• 337 Hong TS, Wo JY, Yeap BY. et al. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 2016; 34 (05) 460-468 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872014/pdf/JCO642710.pdf
• 338 Nakayama H, Sugahara S, Fukuda K. et al. Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract. Int J Radiat Oncol Biol Phys 2011; 80 (04) 992-995
• 339 Nakayama H, Sugahara S, Tokita M. et al. Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer 2009; 115 (23) 5499-506 DOI: 10.1002/cncr.24619?download=true.
• 340 Mizumoto M, Tokuuye K, Sugahara S. et al. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys 2008; 71 (02) 462-467
• 341 Sugahara S, Oshiro Y, Nakayama H. et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010; 76 (02) 460-466
• 342 Santillan C, Chernyak V, Sirlin C. LI-RADS categories: concepts, definitions, and criteria. Abdom Radiol (NY) 2018; 43 (01) 101-110
• 343 Santillan C, Fowler K, Kono Y. et al. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol (NY) 2018; 43 (01) 75-81
• 344 Takahashi S, Kudo M, Chung H. et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 2007; 72 (Suppl. 01) 98-103 https://www.karger.com/Article/Pdf/111714
• 345 Guglielmi A, Ruzzenente A, Pachera S. et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol 2008; 103 (03) 597-604
• 346 Yoon JH, Lee EJ, Cha SS. et al. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol 2010; 21 (03) 348-356
• 347 Vauthey JN, Dixon E, Abdalla EK. et al. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010; 12 (05) 289-299 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951814/pdf/hpb0012-0289.pdf
• 348 Schima W, Ba-Ssalamah A, Kurtaran A. et al. Post-treatment imaging of liver tumours. Cancer Imaging 2007; 7 Spec No A: S28-S36 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727978/pdf/ci079047.pdf
• 349 Frieser M, Kiesel J, Lindner A. et al. Efficacy of contrast-enhanced US versus CT or MRI for the therapeutic control of percutaneous radiofrequency ablation in the case of hepatic malignancies. Ultraschall Med 2011; 32 (02) 148-153 DOI: 10.1055/s-0029-1245934.
• 350 Schacherer D, Girlich C, Jung ME. et al. Transabdominal ultrasound with echoenhancement by contrast media in the diagnosis of hepatocellular carcinoma. Dig Dis 2009; 27 (02) 109-113 https://www.karger.com/Article/Pdf/218342
• 351 Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 2008; 48 (05) 848-857 https://www.sciencedirect.com/science/article/pii/S0168827808001244?via%3Dihub
• 352 Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 2010; 33 (01) 11-17 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816824/pdf/270_2009_Article_9736.pdf
• 353 Tsai MC, Wang JH, Hung CH. et al. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2010; 25 (03) 605-612 DOI: 10.1111/j.1440-1746.2009.06115.x?download=true.
• 354 Lencioni R. New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma. Clin Cancer Res 2013; 19 (06) 1312-1314 https://clincancerres.aacrjournals.org/content/clincanres/19/6/1312.full.pdf
• 355 Vincenzi B, Di Maio M, Silletta M. et al. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS One 2015; 10 (07) e0133488 https://iris.unito.it/retrieve/handle/2318/1572009/162002/pone.0133488.pdf
• 356 Facciorusso A, Tartaglia N, Villani R. et al. Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis. Am J Transl Res 2021; 13 (04) 2379-2387 https://pubmed.ncbi.nlm.nih.gov/34017396
• 357 Finn RS, Qin S, Ikeda M. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382 (20) 1894-1905 DOI: 10.1056/NEJMoa1915745?articleTools=true.
• 358 Cheng AL, Kang YK, Chen Z. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (01) 25-34 https://www.sciencedirect.com/science/article/pii/S1470204508702857?via%3Dihub
• 359 Kudo M, Finn RS, Qin S. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet 2018; 391: 1163-1173
• 360 Bruix J, Qin S, Merle P. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2017; 389: 56-66
• 361 Abou-Alfa GK, Meyer T, Cheng AL. et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018; 379 (01) 54-63 DOI: 10.1056/NEJMoa1717002?articleTools=true.
• 362 Zhu AX, Kang YK, Yen CJ. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20 (02) 282-296
• 363 Llovet JM, Ricci S, Mazzaferro V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (04) 378-390 DOI: 10.1056/NEJMoa0708857?articleTools=true.
• 364 Zhu AX, Kang Y-K, Yen C-J. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2019; 20 (02) 282-296
• 365 Cainap C, Qin S, Huang WT. et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015; 33 (02) 172-179 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279237/pdf/zlj172.pdf
• 366 Johnson PJ, Qin S, Park JW. et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31 (28) 3517-3524
• 367 Zhu AX, Rosmorduc O, Evans TR. et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015; 33 (06) 559-566 http://diposit.ub.edu/dspace/bitstream/2445/117402/1/649304.pdf
• 368 Cheng AL, Kang YK, Lin DY. et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31 (32) 4067-4075
• 369 Marrero JA, Kudo M, Venook AP. et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol 2016; 65 (06) 1140-1147 https://www.journal-of-hepatology.eu/article/S0168-8278(16)30346-4/pdf
• 370 Ganten TM, Stauber RE, Schott E. et al. Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study. Clin Cancer Res 2017; 23 (19) 5720-5728 https://clincancerres.aacrjournals.org/content/clincanres/23/19/5720.full.pdf
• 371 Leal CRG, Magalhães C, Barbosa D. et al. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study. Invest New Drugs 2018; 36 (05) 911-918 DOI: 10.1007/s10637-018-0621-x.
• 372 Pressiani T, Boni C, Rimassa L. et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013; 24 (02) 406-411 https://www.annalsofoncology.org/article/S0923-7534(19)36863-2/pdf
• 373 Ogasawara S, Chiba T, Ooka Y. et al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 2015; 33 (03) 729-739 https://link.springer.com/article/10.1007%2Fs10637-015-0237-3
• 374 Kudo M, Matilla A, Santoro A. et al. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol 2021; 75 (03) 600-609 https://pubmed.ncbi.nlm.nih.gov/34051329
• 375 Scheiner B, Kirstein MM, Hucke F. et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther 2019; 49 (10) 1323-1333 https://pubmed.ncbi.nlm.nih.gov/30980420
• 376 Spahn S, Roessler D, Pompilia R. et al. Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers (Basel) 2020; 12 (12) 3830 https://pubmed.ncbi.nlm.nih.gov/33353145
• 377 Kambhampati S, Bauer KE, Bracci PM. et al. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer 2019; 125 (18) 3234-3241 DOI: 10.1002/cncr.32206?download=true.
• 378 Vilgrain V, Pereira H, Assenat E. et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017; 18 (12) 1624-1636 https://www.sciencedirect.com/science/article/abs/pii/S1470204517306836
• 379 Lencioni R, Llovet JM, Han G. et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 2016; 64 (05) 1090-1098 https://www.ncbi.nlm.nih.gov/pubmed/26809111
• 380 Meyer T, Fox R, Ma YT. et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2 (08) 565-575 https://www.thelancet.com/pdfs/journals/langas/PIIS2468-1253(17)30156-5.pdf
• 381 Ricke J, Klümpen HJ, Amthauer H. et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 2019; 71 (06) 1164-1174 https://www.journal-of-hepatology.eu/article/S0168-8278(19)30472-6/fulltext
• 382 Kudo M, Ueshima K, Ikeda M. et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020; 69 (08) 1492-1501 https://www.ncbi.nlm.nih.gov/pubmed/31801872
• 383 Kudo M, Ikeda M, Ueshima K. et al. Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version). Hepatol Res 2019; 49 (09) 981-989 https://www.ncbi.nlm.nih.gov/pubmed/31231916
• 384 Kudo M, Ueshima K, Ikeda M. et al. TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC). Journal of Clinical Oncology 2021; 39 (03) 270-270 DOI: 10.1200/JCO.2021.39.3_suppl.270.
• 385 Bruix J, Qin S, Merle P. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56-66 https://www.sciencedirect.com/science/article/pii/S0140673616324539?via%3Dihub
• 386 Reig M, Rimola J, Torres F. et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 2013; 58 (06) 2023-2031 DOI: 10.1002/hep.26586?download=true.
• 387 Finn RS, Ryoo BY, Merle P. et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2020; 38 (03) 193-202 https://pubmed.ncbi.nlm.nih.gov/31790344
• 388 He S, Jiang W, Fan K. et al. The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2021; 11: 626984 https://pubmed.ncbi.nlm.nih.gov/33833987
• 389 Parikh ND, Marshall A, Betts KA. et al. Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. J Comp Eff Res 2021; 10 (05) 343-352 https://pubmed.ncbi.nlm.nih.gov/33442996
• 390 Rao Q, Li M, Xu W. et al. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int 2020; 14 (05) 765-775 https://pubmed.ncbi.nlm.nih.gov/32572818
• 391 Yau T, Kang YK, Kim TY. et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol 2020; 6 (11) e204564 https://pubmed.ncbi.nlm.nih.gov/33001135
• 392 El-Khoueiry AB, Sangro B, Yau T. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase ½ dose escalation and expansion trial. Lancet 2017; 389: 2492-2502 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539326/pdf/nihms-1623792.pdf
• 393 Zhu AX, Finn RS, Edeline J. et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19 (07) 940-952 https://www.ncbi.nlm.nih.gov/pubmed/29875066
• 394 Finn RS, Ryoo BY, Merle P. et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2020; 38 (03) 193-202 https://www.ncbi.nlm.nih.gov/pubmed/31790344
• 395 Katzenstein HM, Krailo MD, Malogolowkin MH. et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children‘s Cancer Group intergroup study. J Clin Oncol 2002; 20 (12) 2789-2797
• 396 Czauderna P, Mackinlay G, Perilongo G. et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002; 20 (12) 2798-2804 https://www.ncbi.nlm.nih.gov/pubmed/12065556
• 397 Schmid I, von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. J Hepatocell Carcinoma 2017; 4: 15-21 https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1606928529_5fc7c891ac97c/JHC-94008-pediatric-hepatocellular-carcinoma---challenges-and-solution_011617.pdf
• 398 Schmid I, Häberle B, Albert MH. et al. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer 2012; 58 (04) 539-544 DOI: 10.1002/pbc.23295.
• 399 Schütte K, Tippelt B, Schulz C. et al. Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). Clin Nutr 2015; 34 (06) 1122-1127
• 400 Huang TH, Hsieh CC, Kuo LM. et al. Malnutrition associated with an increased risk of postoperative complications following hepatectomy in patients with hepatocellular carcinoma. HPB (Oxford) 2019; 21 (09) 1150-1155
• 401 Arends J, Bachmann P, Baracos V. et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017; 36 (01) 11-48
• 402 Ciuni R, Biondi A, Grosso G. et al. Nutritional aspects in patient undergoing liver resection. Updates Surg 2011; 63 (04) 249-252 DOI: 10.1007/s13304-011-0121-4.
• 403 Cederholm T, Jensen GL, Correia MITD. et al. GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle 2019; 10 (01) 207-217 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438340/pdf/JCSM-10-207.pdf
• 404 Fujiwara N, Nakagawa H, Kudo Y. et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 2015; 63 (01) 131-140
• 405 Badran H, Elsabaawy MM, Ragab A. et al. Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients. Asian Pac J Cancer Prev 2020; 21 (11) 3285-3290 http://journal.waocp.org/article_89349_cc643ce4770cf7eeca5890c5d5c453d5.pdf
• 406 Kim N, Yu JI, Park HC. et al. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunol Immunother 2020; DOI: 10.1007/s00262-020-02794-3.
• 407 Mardian Y, Yano Y, Ratnasari N. et al. „Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study“. BMC Gastroenterol 2019; 19 (01) 229 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937974/pdf/12876_2019_Article_1152.pdf
• 408 Voron T, Tselikas L, Pietrasz D. et al. Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma. Ann Surg 2015; 261 (06) 1173-1183
• 409 Plauth M, Bernal W, Dasarathy S. et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr 2019; 38 (02) 485-521 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686849/pdf/nihms-1529826.pdf
• 410 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung. Version 2.2, 2020. https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmedizin
• 411 Haun MW, Estel S, Rucker G. et al. Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev 2017; 6: CD011129 http://www.ncbi.nlm.nih.gov/pubmed/28603881
• 412 Adler K, Schlieper D, Kindgen-Milles D. et al. [Integration of palliative care into intensive care: Systematic review]. Anaesthesist 2017; 66 (09) 660-666 http://www.ncbi.nlm.nih.gov/pubmed/28589374
• 413 Dalgaard KM, Bergenholtz H, Nielsen ME. et al. Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome. Palliat Support Care 2014; 12 (06) 495-513 http://www.ncbi.nlm.nih.gov/pubmed/24621947
• 414 Davis MP, Temel JS, Balboni T. et al. A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses. Ann Palliat Med 2015; 4 (03) 99-121 http://www.ncbi.nlm.nih.gov/pubmed/26231807
• 415 Hui D, Kim YJ, Park JC. et al. Integration of oncology and palliative care: a systematic review. Oncologist 2015; 20 (01) 77-83 http://www.ncbi.nlm.nih.gov/pubmed/25480826
• 416 Hui D, Meng YC, Bruera S. et al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review. Oncologist 2016; 21 (07) 895-901 http://www.ncbi.nlm.nih.gov/pubmed/27185614
• 417 Tassinari D, Drudi F, Monterubbianesi MC. et al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature. Rev Recent Clin Trials 2016; 11 (01) 63-71 http://www.ncbi.nlm.nih.gov/pubmed/26464077
• 418 Gärtner U, Braun GD, Held K. et al. [Physical complaints, stress and quality of life of oncologic patients. Effects and patient assessment in inpatient rehabilitation]. Med Klin (Munich) 1996; 91 (08) 501-508
• 419 Hamano J, Morita T, Inoue S. et al. Surprise Questions for Survival Prediction in Patients With Advanced Cancer: A Multicenter Prospective Cohort Study. Oncologist 2015; 20 (07) 839-844 http://www.ncbi.nlm.nih.gov/pubmed/26054631
• 420 Moroni M, Zocchi D, Bolognesi D. et al. The “surprise” question in advanced cancer patients: A prospective study among general practitioners. Palliat Med 2014; 28 (07) 959-964 http://www.ncbi.nlm.nih.gov/pubmed/24662237
• 421 Murray S, Boyd K. Using the “surprise question” can identify people with advanced heart failure and COPD who would benefit from a palliative care approach. Palliat Med 2011; 25 (04) 382 http://www.ncbi.nlm.nih.gov/pubmed/21610113
• 422 Moss AH, Lunney JR, Culp S. et al. Prognostic significance of the „surprise“ question in cancer patients. J Palliat Med 2010; 13 (07) 837-840 http://www.ncbi.nlm.nih.gov/pubmed/20636154
• 423 Kremer AE, Beuers U, Oude-Elferink RP. et al. Pathogenesis and treatment of pruritus in cholestasis. Drugs 2008; 68 (15) 2163-2182 http://www.ncbi.nlm.nih.gov/pubmed/18840005
• 424 Stander S, Zeidler C, Augustin M. et al. S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus – Update – Kurzversion. J Dtsch Dermatol Ges 2017; 15 (08) 860-873 http://www.ncbi.nlm.nih.gov/pubmed/28763608
• 425 Stander S, Raap U, Weisshaar E. et al. Pathogenesis of pruritus. J Dtsch Dermatol Ges 2011; 9 (06) 456-463 http://www.ncbi.nlm.nih.gov/pubmed/21208378
• 426 Bachs L, Pares A, Elena M. et al. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 1: 574-576 http://www.ncbi.nlm.nih.gov/pubmed/2564110
• 427 Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94 (02) 488-493 http://www.ncbi.nlm.nih.gov/pubmed/3275568
• 428 Terg R, Coronel E, Sorda J. et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37 (06) 717-722 http://www.ncbi.nlm.nih.gov/pubmed/12445410
• 429 Bergasa NV, Talbot TL, Alling DW. et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102 (02) 544-549 http://www.ncbi.nlm.nih.gov/pubmed/1732125
• 430 Mayo MJ, Handem I, Saldana S. et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007; 45 (03) 666-674 http://www.ncbi.nlm.nih.gov/pubmed/17326161
• 431 Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336 (10) 691-695 http://www.ncbi.nlm.nih.gov/pubmed/9041099
• 432 Talwalkar JA, Souto E, Jorgensen RA. et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003; 1 (04) 297-302 http://www.ncbi.nlm.nih.gov/pubmed/15017671
• 433 Zapata R, Sandoval L, Palma J. et al. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience. Liver Int 2005; 25 (03) 548-554 http://www.ncbi.nlm.nih.gov/pubmed/15910492
• 434 Lemyze M, Dharancy S, Nevière R. et al. Aerobic capacity in patients with chronic liver disease: Very modest effect of liver transplantation. Presse Med 2010; 39 (07) e174-e181
• 435 Epstein SK, Freeman RB, Khayat A. et al. Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transpl 2004; 10 (03) 418-424 DOI: 10.1002/lt.20088?download=true.
• 436 van Ginneken BT, van den Berg-Emons RJ, Kazemier G. et al. Physical fitness, fatigue, and quality of life after liver transplantation. Eur J Appl Physiol 2007; 100 (03) 345-353 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1914221/pdf/421_2007_Article_435.pdf
• 437 van den Berg-Emons R, van Ginneken B, Wijffels M. et al. Fatigue is a major problem after liver transplantation. Liver Transpl 2006; 12 (06) 928-933 DOI: 10.1002/lt.20684?download=true.
• 438 van Ginneken BT, van den Berg-Emons HJ, Metselaar HJ. et al. Effects of a rehabilitation programme on daily functioning, participation, health-related quality of life, anxiety and depression in liver transplant recipients. Disabil Rehabil 2010; 32 (25) 2107-2112 DOI: 10.3109/09638288.2010.482174.
• 439 Schwibbe G. [Changes in quality of life in oncological patients in the course of an inpatient after-care program]. Rehabilitation (Stuttg) 1991; 30 (02) 55-62
• 440 Fan SY, Eiser C, Ho MC. et al. Health-related quality of life in patients with hepatocellular carcinoma: the mediation effects of illness perceptions and coping. Psychooncology 2013; 22 (06) 1353-1360 DOI: 10.1002/pon.3146?download=true.
• 441 Fan SY, Eiser C, Ho MC. Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroenterol Hepatol 2010; 8 (07) 559-564.e1-e10 https://www.sciencedirect.com/science/article/abs/pii/S1542356510002533?via%3Dihub
• 442 Qiao CX, Zhai XF, Ling CQ. et al. Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma. World J Gastroenterol 2012; 18 (21) 2689-2694 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370007/pdf/WJG-18-2689.pdf
• 443 Steel JL, Geller DA, Gamblin TC. et al. Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol 2007; 25 (17) 2397-2405
• 444 Lee HH, Chiu CC, Lin JJ. et al. Impact of preoperative anxiety and depression on quality of life before and after resection of hepatocellular carcinoma. J Affect Disord 2019; 246: 361-367 https://www.sciencedirect.com/science/article/abs/pii/S0165032718318639?via%3Dihub
• 445 Huang TW, Lin CC. The mediating effects of depression on sleep disturbance and fatigue: symptom clusters in patients with hepatocellular carcinoma. Cancer Nurs 2009; 32 (05) 398-403
• 446 Ahn MH, Park S, Lee HB. et al. Suicide in cancer patients within the first year of diagnosis. Psychooncology 2015; 24 (05) 601-607 DOI: 10.1002/pon.3705?download=true.
• 447 Chiu CC, Lee KT, Wang JJ. et al. Health-Related Quality of Life before and after Surgical Resection of Hepatocellular Carcinoma: A Prospective Study. Asian Pac J Cancer Prev 2018; 19 (01) 65-72 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844638/pdf/APJCP-19-65.pdf
• 448 Shun SC, Chen CH, Sheu JC. et al. Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. Oncologist 2012; 17 (05) 732-739 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360913/pdf/onc732.pdf
• 449 Shun SC, Lai YH, Hung H. et al. The Role of Age in Change in Unmet Supportive Care Needs in Hepatocellular Carcinoma Patients During Transition From Hospital to Home. Cancer Nurs 2017; 40 (03) 245-254
• 450 Wang ZX, Liu SL, Sun CH. et al. Psychological intervention reduces postembolization pain during hepatic arterial chemoembolization therapy: a complementary approach to drug analgesia. World J Gastroenterol 2008; 14 (06) 931-935 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687062/pdf/WJG-14-931.pdf
• 451 Sanson-Fisher R, Girgis A, Boyes A. et al. The unmet supportive care needs of patients with cancer. Supportive Care Review Group. Cancer 2000; 88 (01) 226-237 DOI: 10.1002/%28SICI%291097-0142%2820000101%2988%3A1%3C226%3A%3AAID-CNCR30%3E3.0.CO%3B2-P?download=true.
• 452 Kleeberg UR, Tews JT, Ruprecht T. et al. Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study. Support Care Cancer 2005; 13 (05) 303-310 DOI: 10.1007/s00520-004-0727-x.
• 453 Fallowfield L, Jenkins V. Communicating sad, bad, and difficult news in medicine. Lancet 2004; 363: 312-319
• 454 Ong LM, Visser MR, Lammes FB. et al. Doctor-patient communication and cancer patients’ quality of life and satisfaction. Patient Educ Couns 2000; 41 (02) 145-156
• 455 de Haes H, Teunissen S. Communication in palliative care: a review of recent literature. Curr Opin Oncol 2005; 17 (04) 345-350
• 456 Fukui S, Ogawa K, Ohtsuka M. et al. A randomized study assessing the efficacy of communication skill training on patients’ psychologic distress and coping: nurses’ communication with patients just after being diagnosed with cancer. Cancer 2008; 113 (06) 1462-1470 DOI: 10.1002/cncr.23710?download=true.
• 457 Razavi D, Merckaert I, Marchal S. et al. How to optimize physicians’ communication skills in cancer care: results of a randomized study assessing the usefulness of posttraining consolidation workshops. J Clin Oncol 2003; 21 (16) 3141-3149
• 458 Lienard A, Merckaert I, Libert Y. et al. Factors that influence cancer patients’ and relatives’ anxiety following a three-person medical consultation: impact of a communication skills training program for physicians. Psychooncology 2008; 17 (05) 488-496 DOI: 10.1002/pon.1262?download=true.
• 459 Edwards A, Elwyn G. Inside the black box of shared decision making: distinguishing between the process of involvement and who makes the decision. Health Expect 2006; 9 (04) 307-320 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5060371/pdf/HEX-9-307.pdf
• 460 Butow P, Juraskova I, Chang S. et al. Shared decision making coding systems: how do they compare in the oncology context?. Patient Educ Couns 2010; 78 (02) 261-268
• 461 Gordon EJ, Bergeron A, McNatt G. et al. Are informed consent forms for organ transplantation and donation too difficult to read?. Clin Transplant 2012; 26 (02) 275-283 DOI: 10.1111/j.1399-0012.2011.01480.x?download=true.
• 462 Volk ML, Tocco RS, Pelletier SJ. et al. Patient decision making about organ quality in liver transplantation. Liver Transpl 2011; 17 (12) 1387-1393 https://deepblue.lib.umich.edu/bitstream/handle/2027.42/88081/22437_ftp.pdf?sequence=1
• 463 Rodrigue JR, Hanto DW, Curry MP. Patients’ expectations and success criteria for liver transplantation. Liver Transpl 2011; 17 (11) 1309-1317 DOI: 10.1002/lt.22355?download=true.
• 464 Butow PN, Tattersall MH, Goldstein D. Communication with cancer patients in culturally diverse societies. Ann N Y Acad Sci 1997; 809: 317-329 DOI: 10.1111/j.1749-6632.1997.tb48095.x?download=true.
• 465 Dowsett SM, Saul JL, Butow PN. et al. Communication styles in the cancer consultation: preferences for a patient-centred approach. Psychooncology 2000; 9 (02) 147-156 DOI: 10.1002/%28SICI%291099-1611%28200003/04%299%3A2%3C147%3A%3AAID-PON443%3E3.0.CO%3B2-X?download=true.
• 466 Epstein RM. Making communication research matter: what do patients notice, what do patients want, and what do patients need?. Patient Educ Couns 2006; 60 (03) 272-278
• 467 Zachariae R, Pedersen CG, Jensen AB. et al. Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease. Br J Cancer 2003; 88 (05) 658-665 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376357/pdf/88-6600798a.pdf
• 468 Strasser F, Palmer JL, Willey J. et al. Impact of physician sitting versus standing during inpatient oncology consultations: patients’ preference and perception of compassion and duration. A randomized controlled trial. J Pain Symptom Manage 2005; 29 (05) 489-497
• 469 Fogarty LA, Curbow BA, Wingard JR. et al. Can 40 seconds of compassion reduce patient anxiety?. J Clin Oncol 1999; 17 (01) 371-379
• 470 Atchison EA, Gridley G, Carreon JD. et al. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 2011; 128 (03) 635-643 DOI: 10.1002/ijc.25362?download=true.
• 471 de Valle MB, Björnsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int 2012; 32 (03) 441-448 DOI: 10.1111/j.1478-3231.2011.02614.x?download=true.
• 472 El-Serag HB, Engels EA, Landgren O. et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology 2009; 49 (01) 116-123 DOI: 10.1002/hep.22606?download=true.
• 473 Huang Y, You L, Xie W. et al. Smoking and risk of cholangiocarcinoma: a systematic review and meta-analysis. Oncotarget 2017; 8 (59) 100570-100581 https://www.oncotarget.com/article/20141/pdf
• 474 Jing W, Jin G, Zhou X. et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev 2012; 21 (01) 24-31
• 475 Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57 (01) 69-76 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804834/pdf/nihms363811.pdf
• 476 Wongjarupong N, Assavapongpaiboon B, Susantitaphong P. et al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2017; 17 (01) 149 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721586/pdf/12876_2017_Article_696.pdf
• 477 Park JY, Hong SP, Kim YJ. et al. Long-term follow up of gallbladder polyps. J Gastroenterol Hepatol 2009; 24 (02) 219-222 DOI: 10.1111/j.1440-1746.2008.05689.x?download=true.
• 478 Nagaraja V, Eslick GD. Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer. Aliment Pharmacol Ther 2014; 39 (08) 745-750 DOI: 10.1111/apt.12655?download=true.
• 479 Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014; 383: 2168-2179 https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(13)61903-0.pdf
• 480 Rizvi S, Khan SA, Hallemeier CL. et al. Cholangiocarcinoma – evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 2018; 15 (02) 95-111
• 481 Valle JW, Borbath I, Khan SA. et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl. 05) v28-v37 https://pubmed.ncbi.nlm.nih.gov/27664259
• 482 Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013; 145 (06) 1215-1229 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862291/pdf/nihms535439.pdf
• 483 Kamsa-ard S, Luvira V, Suwanrungruang K. et al. Risk Factors for Cholangiocarcinoma in Thailand: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev 2018; 19 (03) 605-614 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980830/pdf/APJCP-19-605.pdf
• 484 Qian MB, Utzinger J, Keiser J. et al. Clonorchiasis. Lancet 2016; 387: 800-810
• 485 Qian MB, Zhou XN. Global burden of cancers attributable to liver flukes. Lancet Glob Health 2017; 5 (02) e139
• 486 You MS, Lee SH, Kang J. et al. Natural Course and Risk of Cholangiocarcinoma in Patients with Recurrent Pyogenic Cholangitis: A Retrospective Cohort Study. Gut Liver 2019; 13 (03) 373-379 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529165/pdf/gnl-13-373.pdf
• 487 Ten Hove A, de Meijer VE, Hulscher JBF. et al. Meta-analysis of risk of developing malignancy in congenital choledochal malformation. Br J Surg 2018; 105 (05) 482-490 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900735/pdf/BJS-105-482.pdf
• 488 Fahrner R, Dennler SG, Inderbitzin D. Risk of malignancy in Caroli disease and syndrome: A systematic review. World J Gastroenterol 2020; 26 (31) 4718-4728 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445861/pdf/WJG-26-4718.pdf
• 489 Claessen MM, Vleggaar FP, Tytgat KM. et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50 (01) 158-164
• 490 Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011; 54 (01) 173-184 DOI: 10.1002/hep.24351?download=true.
• 491 McGee EE, Jackson SS, Petrick JL. et al. Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. J Natl Cancer Inst 2019; 111 (12) 1263-1278 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910180/pdf/djz103.pdf
• 492 Clements O, Eliahoo J, Kim JU. et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J Hepatol 2020; 72 (01) 95-103
• 493 Schmidt MA, Marcano-Bonilla L, Roberts LR. Gallbladder cancer: epidemiology and genetic risk associations. Chin Clin Oncol 2019; 8 (04) 31 http://cco.amegroups.com/article/view/28517/25064
• 494 Rawla P, Sunkara T, Thandra KC. et al. Epidemiology of gallbladder cancer. Clin Exp Hepatol 2019; 5 (02) 93-102 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728871/pdf/CEH-5-36699.pdf
• 495 Kratzer W, Schmid A, Akinli AS. et al. [Gallbladder polyps: prevalence and risk factors]. Ultraschall Med 2011; 32 (Suppl. 01) S68-S73 DOI: 10.1055/s-0029-1245265.
• 496 Schnelldorfer T. Porcelain gallbladder: a benign process or concern for malignancy?. J Gastrointest Surg 2013; 17 (06) 1161-1168 DOI: 10.1007/s11605-013-2170-0.
• 497 DesJardins H, Duy L, Scheirey C. et al. Porcelain Gallbladder: Is Observation a Safe Option in Select Populations?. J Am Coll Surg 2018; 226 (06) 1064-1069 https://www.sciencedirect.com/science/article/abs/pii/S1072751518301571?via%3Dihub
• 498 Patel S, Roa JC, Tapia O. et al. Hyalinizing cholecystitis and associated carcinomas: clinicopathologic analysis of a distinctive variant of cholecystitis with porcelain-like features and accompanying diagnostically challenging carcinomas. Am J Surg Pathol 2011; 35 (08) 1104-1113
• 499 Gutt C, Jenssen C, Barreiros AP. et al. [Updated S3-Guideline for Prophylaxis, Diagnosis and Treatment of Gallstones. German Society for Digestive and Metabolic Diseases (DGVS) and German Society for Surgery of the Alimentary Tract (DGAV) – AWMF Registry 021/008]. Z Gastroenterol 2018; 56 (08) 912-966 DOI: 10.1055/a-0644-2972.
• 500 Eaton JE, Thackeray EW, Lindor KD. Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol 2012; 107 (03) 431-439
• 501 [Practice guideline autoimmune liver diseases – AWMF-Reg. No. 021-27]. Z Gastroenterol 2017; 55 (11) 1135-1226 DOI: 10.1055/s-0043-120199.
• 502 Wiles R, Thoeni RF, Barbu ST. et al. Management and follow-up of gallbladder polyps: Joint guidelines between the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), European Association for Endoscopic Surgery and other Interventional Techniques (EAES), International Society of Digestive Surgery - European Federation (EFISDS) and European Society of Gastrointestinal Endoscopy (ESGE). Eur Radiol 2017; 27 (09) 3856-3866 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544788/pdf/330_2017_Article_4742.pdf
• 503 Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World J Gastroenterol 2019; 25 (06) 659-671 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378537/pdf/WJG-25-659.pdf
• 504 Charatcharoenwitthaya P, Enders FB, Halling KC. et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008; 48 (04) 1106-1117 DOI: 10.1002/hep.22441?download=true.
• 505 Naitoh I, Nakazawa T, Kato A. et al. Predictive factors for positive diagnosis of malignant biliary strictures by transpapillary brush cytology and forceps biopsy. J Dig Dis 2016; 17 (01) 44-51 DOI: 10.1111/1751-2980.12311.
• 506 Navaneethan U, Njei B, Lourdusamy V. et al. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc 2015; 81 (01) 168-176 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824293/pdf/nihms773255.pdf
• 507 Klimstra DS, Lam AK, Paradis V. et al. Tumors of the gallbladder and extrahepatic bile ducts. In: WHO Classification of Tumours Editorial Board WHO-Classification of Tumours (5th ed.) Digestive System Tumours. International Agency for Research on Cancer,. Lyon: 2019: 265-294
• 508 Moeini A, Sia D, Zhang Z. et al. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol 2017; 66 (05) 952-961
• 509 Paradis V, Schirmacher P, Singh R. Other tumours of the digestive system. In: WHO Classification of Tumours Editorial Board WHO-Classification of Tumours (5th ed.) Digestive System Tumours. International Agency for Research on Cancer,. Lyon: 2019: 499-510
• 510 Wittekind C. TNM-Klassifikation maligner Tumoren. (8. Auflage, korrigierter Nachdruck). Weinheim: Wiley-VCH; 2020
• 511 Wagner G, Hermanek P. Organspezifische Tumordokumentation – Prinzipien und Verschlüsselungsanweisungen für Klinik und Praxis. Online-version: deutsche Krebsgesellschaft. Frankfurt (Main): 1995
• 512 Khuntikeo N, Chamadol N, Yongvanit P. et al. Cohort profile: cholangiocarcinoma screening and care program (CASCAP). BMC Cancer 2015; 15: 459 https://www.ncbi.nlm.nih.gov/pubmed/26054405
• 513 Li R, Zhang X, Ma KS. et al. Dynamic enhancing vascular pattern of intrahepatic peripheral cholangiocarcinoma on contrast-enhanced ultrasound: the influence of chronic hepatitis and cirrhosis. Abdom Imaging 2013; 38 (01) 112-119 https://link.springer.com/content/pdf/10.1007%2Fs00261-012-9854-x.pdf
• 514 Xu HX, Chen LD, Liu LN. et al. Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination. Br J Radiol 2012; 85: 1029-1037 https://www.ncbi.nlm.nih.gov/pubmed/22374276
• 515 Wildner D, Bernatik T, Greis C. et al. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients – early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med 2015; 36 (02) 132-139 10.1055/s-0034-1399147.pdf
• 516 Bach AM, Hann LE, Brown KT. et al. Portal vein evaluation with US: comparison to angiography combined with CT arterial portography. Radiology 1996; 201 (01) 149-154 https://www.ncbi.nlm.nih.gov/pubmed/8816536
• 517 Wennmacker SZ, Lamberts MP, Di Martino M. et al. Transabdominal ultrasound and endoscopic ultrasound for diagnosis of gallbladder polyps. Cochrane Database Syst Rev 2018; 8: CD012233 https://www.ncbi.nlm.nih.gov/pubmed/30109701
• 518 Zhang Y, Uchida M, Abe T. et al. Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI. J Comput Assist Tomogr 1999; 23 (05) 670-677 https://www.ncbi.nlm.nih.gov/pubmed/10524843
• 519 Johnson PT, Fishman EK. Routine use of precontrast and delayed acquisitions in abdominal CT: time for change. Abdom Imaging 2013; 38 (02) 215-223 https://www.ncbi.nlm.nih.gov/pubmed/23132390
• 520 Fabrega-Foster K, Ghasabeh MA, Pawlik TM. et al. Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017; 6 (02) 67-78 https://www.ncbi.nlm.nih.gov/pubmed/28503554
• 521 Valls C, Guma A, Puig I. et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging 2000; 25 (05) 490-496 https://www.ncbi.nlm.nih.gov/pubmed/10931983
• 522 Kim JH, Won HJ, Shin YM. et al. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. Am J Roentgenol 2011; 196 (02) W205-W209 DOI: 10.2214/Am J Roentgenol.10.4937.
• 523 Bridgewater J, Galle PR, Khan SA. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014; 60 (06) 1268-1289 https://www.ncbi.nlm.nih.gov/pubmed/24681130
• 524 Jhaveri KS, Hosseini-Nik H. MRI of cholangiocarcinoma. J Magn Reson Imaging 2015; 42 (05) 1165-1179 https://www.ncbi.nlm.nih.gov/pubmed/25447417
• 525 Murakami T, Nakamura H, Tsuda K. et al. Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study. J Magn Reson Imaging 1995; 5 (02) 165-170 https://www.ncbi.nlm.nih.gov/pubmed/7766977
• 526 Hamrick-Turner J, Abbitt PL, Ros PR. Intrahepatic cholangiocarcinoma: MR appearance. Am J Roentgenol 1992; 158 (01) 77-79 https://www.ncbi.nlm.nih.gov/pubmed/1309221
• 527 Fan ZM, Yamashita Y, Harada M. et al. Intrahepatic cholangiocarcinoma: spin-echo and contrast-enhanced dynamic MR imaging. Am J Roentgenol 1993; 161 (02) 313-317 https://www.ncbi.nlm.nih.gov/pubmed/8392787
• 528 Sheng RF, Zeng MS, Rao SX. et al. MRI of small intrahepatic mass-forming cholangiocarcinoma and atypical small hepatocellular carcinoma (=3 cm) with cirrhosis and chronic viral hepatitis: a comparative study. Clin Imaging 2014; 38 (03) 265-272 https://www.ncbi.nlm.nih.gov/pubmed/24559750
• 529 Chung YE, Kim MJ, Park YN. et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 2009; 29 (03) 683-700 https://www.ncbi.nlm.nih.gov/pubmed/19448110
• 530 Park HJ, Kim YK, Park MJ. et al. Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 2013; 38 (04) 793-801 https://www.ncbi.nlm.nih.gov/pubmed/22829097
• 531 Fattach HE, Dohan A, Guerrache Y. et al. Intrahepatic and hilar mass-forming cholangiocarcinoma: Qualitative and quantitative evaluation with diffusion-weighted MR imaging. Eur J Radiol 2015; 84 (08) 1444-1451 https://www.ncbi.nlm.nih.gov/pubmed/26022518
• 532 Navaneethan U, Njei B, Venkatesh PG. et al. Endoscopic ultrasound in the diagnosis of cholangiocarcinoma as the etiology of biliary strictures: a systematic review and meta-analysis. Gastroenterol Rep (Oxf) 2015; 3 (03) 209-215 https://www.ncbi.nlm.nih.gov/pubmed/25169922
• 533 Pahade JK, Juice D, Staib L. et al. Is there an added value of a hepatobiliary phase with gadoxetate disodium following conventional MRI with an extracellular gadolinium agent in a single imaging session for detection of primary hepatic malignancies?. Abdom Radiol (NY) 2016; 41 (07) 1270-1284 https://link.springer.com/content/pdf/10.1007%2Fs00261-016-0635-9.pdf
• 534 Park HJ, Kim SH, Jang KM. et al. The role of diffusion-weighted MR imaging for differentiating benign from malignant bile duct strictures. Eur Radiol 2014; 24 (04) 947-958 https://www.ncbi.nlm.nih.gov/pubmed/24487774
• 535 Lee J, Kim SH, Kang TW. et al. Mass-forming Intrahepatic Cholangiocarcinoma: Diffusion-weighted Imaging as a Preoperative Prognostic Marker. Radiology 2016; 281 (01) 119-128 https://www.ncbi.nlm.nih.gov/pubmed/27115053
• 536 Rupp C, Hippchen T, Bruckner T. et al. Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut 2019; 68 (12) 2170-2178 https://www.ncbi.nlm.nih.gov/pubmed/30910856
• 537 Zhang H, Zhu J, Ke F. et al. Radiological Imaging for Assessing the Respectability of Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Biomed Res Int 2015; 2015: 497942 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569758/pdf/BMRI2015-497942.pdf
• 538 Lamarca A, Barriuso J, Chander A. et al. (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. J Hepatol 2019; 71 (01) 115-129
• 539 Feng ST, Wu L, Cai H. et al. Cholangiocarcinoma: spectrum of appearances on Gd-EOB-DTPA-enhanced MR imaging and the effect of biliary function on signal intensity. BMC Cancer 2015; 15: 38 https://www.ncbi.nlm.nih.gov/pubmed/25655565
• 540 Kim SH, Lee CH, Kim BH. et al. Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 2012; 36 (06) 704-709 https://www.ncbi.nlm.nih.gov/pubmed/23192208
• 541 De Moura DTH, Moura EGH, Bernardo WM. et al. Endoscopic retrograde cholangiopancreatography versus endoscopic ultrasound for tissue diagnosis of malignant biliary stricture: Systematic review and meta-analysis. Endosc Ultrasound 2018; 7 (01) 10-19 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838722/pdf/EUS-7-10.pdf
• 542 Heimbach JK, Sanchez W, Rosen CB. et al. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford) 2011; 13 (05) 356-360 https://www.ncbi.nlm.nih.gov/pubmed/21492336
• 543 El Chafic AH, Dewitt J, Leblanc JK. et al. Impact of preoperative endoscopic ultrasound-guided fine needle aspiration on postoperative recurrence and survival in cholangiocarcinoma patients. Endoscopy 2013; 45 (11) 883-889 https://www.ncbi.nlm.nih.gov/pubmed/24165813
• 544 Korc P, Sherman S. ERCP tissue sampling. Gastrointest Endosc 2016; 84 (04) 557-571 https://www.ncbi.nlm.nih.gov/pubmed/27156656
• 545 Fogel EL, deBellis M, McHenry L. et al. Effectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: a prospective study. Gastrointest Endosc 2006; 63 (01) 71-77 https://www.ncbi.nlm.nih.gov/pubmed/16377319
• 546 Shieh FK, Luong-Player A, Khara HS. et al. Improved endoscopic retrograde cholangiopancreatography brush increases diagnostic yield of malignant biliary strictures. World J Gastrointest Endosc 2014; 6 (07) 312-317 https://www.ncbi.nlm.nih.gov/pubmed/25031790
• 547 Glasbrenner B, Ardan M, Boeck W. et al. Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography. Endoscopy 1999; 31 (09) 712-717 https://www.ncbi.nlm.nih.gov/pubmed/10604612
• 548 Macken E, Drijkoningen M, Van Aken E. et al. Brush cytology of ductal strictures during ERCP. Acta Gastroenterol Belg 2000; 63 (03) 254-259 https://www.ncbi.nlm.nih.gov/pubmed/11189981
• 549 Mansfield JC, Griffin SM, Wadehra V. et al. A prospective evaluation of cytology from biliary strictures. Gut 1997; 40 (05) 671-677 https://www.ncbi.nlm.nih.gov/pubmed/9203949
• 550 Trikudanathan G, Navaneethan U, Njei B. et al. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014; 79 (05) 783-789 https://www.ncbi.nlm.nih.gov/pubmed/24140129
• 551 Draganov PV, Chauhan S, Wagh MS. et al. Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study. Gastrointest Endosc 2012; 75 (02) 347-353 https://www.ncbi.nlm.nih.gov/pubmed/22248602
• 552 Sugiyama M, Atomi Y, Wada N. et al. Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary strictures: a prospective comparative study with bile and brush cytology. Am J Gastroenterol 1996; 91 (03) 465-467 https://www.ncbi.nlm.nih.gov/pubmed/8633492
• 553 Jailwala J, Fogel EL, Sherman S. et al. Triple-tissue sampling at ERCP in malignant biliary obstruction. Gastrointest Endosc 2000; 51 (04) 383-390 https://www.ncbi.nlm.nih.gov/pubmed/10744806
• 554 Hartman DJ, Slivka A, Giusto DA. et al. Tissue yield and diagnostic efficacy of fluoroscopic and cholangioscopic techniques to assess indeterminate biliary strictures. Clin Gastroenterol Hepatol 2012; 10 (09) 1042-1046 https://www.ncbi.nlm.nih.gov/pubmed/22677575
• 555 Pugliese V, Conio M, Nicolo G. et al. Endoscopic retrograde forceps biopsy and brush cytology of biliary strictures: a prospective study. Gastrointest Endosc 1995; 42 (06) 520-526 https://www.ncbi.nlm.nih.gov/pubmed/8674921
• 556 Kitajima Y, Ohara H, Nakazawa T. et al. Usefulness of transpapillary bile duct brushing cytology and forceps biopsy for improved diagnosis in patients with biliary strictures. J Gastroenterol Hepatol 2007; 22 (10) 1615-1620 https://www.ncbi.nlm.nih.gov/pubmed/17573833
• 557 Navaneethan U, Hasan MK, Lourdusamy V. et al. Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review. Gastrointest Endosc 2015; 82 (04) 608-614.e2 https://www.ncbi.nlm.nih.gov/pubmed/26071061
• 558 Gerges C, Beyna T, Tang RSY. et al. Digital single-operator peroral cholangioscopy-guided biopsy versus ERCP-guided brushing for indeterminate biliary strictures: a prospective, randomized multicenter trial (with video). Gastrointest Endosc 2019; https://www.ncbi.nlm.nih.gov/pubmed/31778656 DOI: 10.1016/j.gie.2019.11.025.
• 559 Aabakken L, Karlsen TH, Albert J. et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy 2017; 49 (06) 588-608 DOI: 10.1055/s-0043-107029.
• 560 Bagante F, Spolverato G, Weiss M. et al. Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System. J Gastrointest Surg 2018; 22 (01) 52-59 DOI: 10.1007/s11605-017-3426-x.
• 561 Bagante F, Spolverato G, Weiss M. et al. Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Peri-Operative Outcomes. World J Surg 2018; 42 (08) 2551-2560 DOI: 10.1007/s00268-017-4453-1.
• 562 Ebata T, Mizuno T, Yokoyama Y. et al. Surgical resection for Bismuth type IV perihilar cholangiocarcinoma. Br J Surg 2018; 105 (07) 829-838 DOI: 10.1002/bjs.10556?download=true.
• 563 El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic Cholangiocarcinoma. Surg Oncol Clin N Am 2019; 28 (04) 587-599 https://www.sciencedirect.com/science/article/abs/pii/S1055320719300444?via%3Dihub
• 564 Lang H, Sotiropoulos GC, Sgourakis G. et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 2009; 208 (02) 218-228
• 565 Schnitzbauer AA, Eberhard J, Bartsch F. et al. The MEGNA Score and Preoperative Anemia are Major Prognostic Factors After Resection in the German Intrahepatic Cholangiocarcinoma Cohort. Ann Surg Oncol 2020; 27 (04) 1147-1155 DOI: 10.1245/s10434-019-07968-7.
• 566 Zhang XF, Bagante F, Chakedis J. et al. Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy. J Gastrointest Surg 2017; 21 (11) 1841-1850 DOI: 10.1007/s11605-017-3499-6.
• 567 Bartsch F, Tripke V, Baumgart J. et al. Extended resection of intrahepatic cholangiocarcinoma: A retrospective single-center cohort study. Int J Surg 2019; 67: 62-69 https://www.sciencedirect.com/science/article/abs/pii/S1743919119301116?via%3Dihub
• 568 Mizuno T, Ebata T, Nagino M. Advanced hilar cholangiocarcinoma: An aggressive surgical approach for the treatment of advanced hilar cholangiocarcinoma: Perioperative management, extended procedures, and multidisciplinary approaches. Surg Oncol 2020; 33: 201-206 https://www.sciencedirect.com/science/article/abs/pii/S0960740419302439?via%3Dihub
• 569 Rassam F, Roos E, van Lienden KP. et al. Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience. Langenbecks Arch Surg 2018; 403 (03) 289-307 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986829/pdf/423_2018_Article_1649.pdf
• 570 Primrose JN, Fox RP, Palmer DH. et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019; 20 (05) 663-673 https://www.sciencedirect.com/science/article/abs/pii/S147020451830915X?via%3Dihub
• 571 Le Roy B, Gelli M, Pittau G. et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg 2018; 105 (07) 839-847 DOI: 10.1002/bjs.10641?download=true.
• 572 Chang Y, Li Q, Wu Q. et al. Impact of surgical strategies on the survival of gallbladder cancer patients: analysis of 715 cases. World J Surg Oncol 2020; 18 (01) 142 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320575/pdf/12957_2020_Article_1915.pdf
• 573 Coimbra FJF, Torres OJM, Alikhanov R. et al. BRAZILIAN CONSENSUS ON INCIDENTAL GALLBLADDER CARCINOMA. Arq Bras Cir Dig 2020; 33 (01) e1496 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357549/pdf/0102-6720-abcd-33-01-e1496.pdf
• 574 Sikora SS, Singh RK. Surgical strategies in patients with gallbladder cancer: nihilism to optimism. J Surg Oncol 2006; 93 (08) 670-681 DOI: 10.1002/jso.20535?download=true.
• 575 Søreide K, Guest RV, Harrison EM. et al. Systematic review of management of incidental gallbladder cancer after cholecystectomy. Br J Surg 2019; 106 (01) 32-45 DOI: 10.1002/bjs.11035?download=true.
• 576 Benson 3rd AB, Abrams TA, Ben-Josef E. et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009; 7 (04) 350-391 https://jnccn.org/downloadpdf/journals/jnccn/7/4/article-p350.pdf
• 577 Yuza K, Sakata J, Prasoon P. et al. Long-term outcomes of surgical resection for T1b gallbladder cancer: an institutional evaluation. BMC Cancer 2020; 20 (01) 20 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945689/pdf/12885_2019_Article_6507.pdf
• 578 Lee SE, Jang JY, Kim SW. et al. Surgical strategy for T1 gallbladder cancer: a nationwide multicenter survey in South Korea. Ann Surg Oncol 2014; 21 (11) 3654-3660 DOI: 10.1245/s10434-014-3527-7.
• 579 Bartsch F, Paschold M, Baumgart J. et al. Surgical Resection for Recurrent Intrahepatic Cholangiocarcinoma. World J Surg 2019; 43 (04) 1105-1116 DOI: 10.1007/s00268-018-04876-x.
• 580 Spolverato G, Kim Y, Alexandrescu S. et al. Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection. Ann Surg Oncol 2016; 23 (01) 235-243 DOI: 10.1245/s10434-015-4642-9.
• 581 Seidensticker R, Seidensticker M, Doegen K. et al. Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma. Gastroenterol Res Pract 2016; 2016: 8732521 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758109/pdf/GRP2016-8732521.pdf
• 582 Xu C, Li L, Xu W. et al. Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results. Int J Hyperthermia 2019; 36 (01) 351-358 DOI: 10.1080/02656736.2019.1571247?needAccess=true.
• 583 Zhang SJ, Hu P, Wang N. et al. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 2013; 20 (11) 3596-3602 DOI: 10.1245/s10434-013-3035-1.
• 584 Amini N, Ejaz A, Spolverato G. et al. Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol 2014; 110 (02) 163-170 https://www.ncbi.nlm.nih.gov/pubmed/24676600
• 585 Butros SR, Shenoy-Bhangle A, Mueller PR. et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: feasability, local tumor control, and long-term outcome. Clin Imaging 2014; 38 (04) 490-494 https://www.clinicalimaging.org/article/S0899-7071(14)00040-0/fulltext
• 586 Fu Y, Yang W, Wu W. et al. Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2012; 23 (05) 642-649 https://www.jvir.org/article/S1051-0443(12)00208-4/fulltext
• 587 Han K, Ko HK, Kim KW. et al. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol 2015; 26 (07) 943-948 https://www.jvir.org/article/S1051-0443(15)00250-X/fulltext
• 588 Kolarich AR, Shah JL, George Jr TJ. et al. Non-surgical management of patients with intrahepatic cholangiocarcinoma in the United States, 2004-2015: an NCDB analysis. J Gastrointest Oncol 2018; 9 (03) 536-545 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006029/pdf/jgo-09-03-536.pdf
• 589 Takahashi EA, Kinsman KA, Schmit GD. et al. Thermal ablation of intrahepatic cholangiocarcinoma: Safety, efficacy, and factors affecting local tumor progression. Abdom Radiol (NY) 2018; 43 (12) 3487-3492 DOI: 10.1007/s00261-018-1656-3.
• 590 Kim JH, Won HJ, Shin YM. et al. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol 2011; 80 (03) e221-e225 https://www.ejradiology.com/article/S0720-048X(10)00476-6/fulltext
• 591 Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl 2018; 24 (02) 294-303
• 592 Facciuto ME, Singh MK, Lubezky N. et al. Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation. Transplantation 2015; 99 (01) 151-157
• 593 Vilchez V, Shah MB, Daily MF. et al. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB (Oxford) 2016; 18 (01) 29-34 https://www.hpbonline.org/article/S1365-182X(15)00002-7/pdf
• 594 Sapisochin G, de Lope CR, Gastaca M. et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. Ann Surg 2014; 259 (05) 944-952
• 595 Sapisochin G, Facciuto M, Rubbia-Brandt L. et al. Liver transplantation for „very early“ intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology 2016; 64 (04) 1178-1188
• 596 Lunsford KE, Javle M, Heyne K. et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol 2018; 3 (05) 337-348 https://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30045-1/fulltext
• 597 Becker NS, Rodriguez JA, Barshes NR. et al. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 2008; 12 (01) 117-122 DOI: 10.1007/s11605-007-0335-4.
• 598 Darwish Murad S, Kim WR, Harnois DM. et al Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143 (01) 88-98.e3 ; quiz e14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846443/pdf/nihms507180.pdf
• 599 Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford) 2008; 10 (03) 186-189 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504373/pdf/MHPB10-186.pdf
• 600 Gulamhusein AF, Sanchez W. Liver transplantation in the management of perihilar cholangiocarcinoma. Hepat Oncol 2015; 2 (04) 409-421 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095165/pdf/hep-02-409.pdf
• 601 Ethun CG, Lopez-Aguiar AG, Anderson DJ. et al. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. Ann Surg 2018; 267 (05) 797-805 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002861/pdf/nihms955692.pdf
• 602 Mantel HT, Westerkamp AC, Adam R. et al. Strict Selection Alone of Patients Undergoing Liver Transplantation for Hilar Cholangiocarcinoma Is Associated with Improved Survival. PLoS One 2016; 11 (06) e0156127 https://air.unimi.it/retrieve/handle/2434/465540/799026/journal.pone.0156127.PDF
• 603 Weber SM, Ribero D, O‘Reilly EM. et al. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford) 2015; 17 (08) 669-680
• 604 NCCN Guidelines® for Hepatobiliary Cancers Version 3. 2019
• 605 Ray Jr CE, Edwards A, Smith MT. et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2013; 24 (08) 1218-1226
• 606 Koch C, Franzke C, Bechstein WO. et al. Poor Prognosis of Advanced Cholangiocarcinoma: Real-World Data from a Tertiary Referral Center. Digestion 2019; 1-8
• 607 Gusani NJ, Balaa FK, Steel JL. et al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 2008; 12 (01) 129-137 DOI: 10.1007/s11605-007-0312-y.
• 608 Boehm LM, Jayakrishnan TT, Miura JT. et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 2015; 111 (02) 213-220 DOI: 10.1002/jso.23781.
• 609 Kiefer MV, Albert M, McNally M. et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 2011; 117 (07) 1498-1505 DOI: 10.1002/cncr.25625.
• 610 Vogl TJ, Naguib NN, Nour-Eldin NE. et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. Int J Cancer 2012; 131 (03) 733-740 DOI: 10.1002/ijc.26407.
• 611 Cucchetti A, Cappelli A, Mosconi C. et al. Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: A meta-regression study. Liver Int 2017; 37 (07) 1056-1064 DOI: 10.1111/liv.13382.
• 612 Gangi A, Shah J, Hatfield N. et al. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study. J Vasc Interv Radiol 2018; 29 (08) 1101-1108 https://www.sciencedirect.com/science/article/pii/S1051044318310868?via%3Dihub
• 613 Manceau V, Palard X, Rolland Y. et al. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and (90)Y-loaded glass microsphere selective internal radiation therapy. Eur J Nucl Med Mol Imaging 2018; 45 (10) 1731-1741 https://link.springer.com/content/pdf/10.1007%2Fs00259-018-3990-7.pdf
• 614 Reimer P, Virarkar MK, Binnenhei M. et al. Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-Naïve Patients. Cardiovasc Intervent Radiol 2018; 41 (05) 744-752 DOI: 10.1007/s00270-017-1871-2.
• 615 Yang L, Shan J, Shan L. et al. Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Oncol 2015; 6 (05) 570-588 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570915/pdf/jgo-06-05-570.pdf
• 616 Mosconi C, Solaini L, Vara G. et al. Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis. Cardiovasc Intervent Radiol 2021; 44 (05) 728-738 https://pubmed.ncbi.nlm.nih.gov/33709272
• 617 Zhen Y, Liu B, Chang Z. et al. A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma. Onco Targets Ther 2019; 12: 4489-4498 https://pubmed.ncbi.nlm.nih.gov/31239717
• 618 Hyder O, Marsh JW, Salem R. et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol 2013; 20 (12) 3779-3786 DOI: 10.1245/s10434-013-3127-y.
• 619 Marquardt S, Kirstein MM, Brüning R. et al. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol 2019; 29 (04) 1882-1892 DOI: 10.1007/s00330-018-5729-z.
• 620 Edeline J, Touchefeu Y, Guiu B. et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol 2019; 6 (01) 51-59 https://jamanetwork.com/journals/jamaoncology/articlepdf/2753557/jamaoncology_edeline_2019_oi_190074.pdf
• 621 Konstantinidis IT, Groot Koerkamp B, Do RK. et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 2016; 122 (05) 758-765 DOI: 10.1002/cncr.29824?download=true.
• 622 Al-Adra DP, Gill RS, Axford SJ. et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 2015; 41 (01) 120-127
• 623 Wronka KM, Grąt M, Stypułkowski J. et al. Relevance of Preoperative Hyperbilirubinemia in Patients Undergoing Hepatobiliary Resection for Hilar Cholangiocarcinoma. J Clin Med 2019; 8 (04) DOI: 10.3390/jcm8040458. https://res.mdpi.com/d_attachment/jcm/jcm-08-00458/article_deploy/jcm-08-00458.pdf
• 624 Al Mahjoub A, Menahem B, Fohlen A. et al. Preoperative Biliary Drainage in Patients with Resectable Perihilar Cholangiocarcinoma: Is Percutaneous Transhepatic Biliary Drainage Safer and More Effective than Endoscopic Biliary Drainage? A Meta-Analysis. J Vasc Interv Radiol 2017; 28 (04) 576-582
• 625 Hameed A, Pang T, Chiou J. et al. Percutaneous vs. endoscopic pre-operative biliary drainage in hilar cholangiocarcinoma – a systematic review and meta-analysis. HPB (Oxford) 2016; 18 (05) 400-410 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857062/pdf/main.pdf
• 626 Coelen RJS, Roos E, Wiggers JK. et al. Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol 2018; 3 (10) 681-690 https://www.sciencedirect.com/science/article/abs/pii/S2468125318302346?via%3Dihub
• 627 Ba Y, Yue P, Leung JW. et al. Percutaneous transhepatic biliary drainage may be the preferred preoperative drainage method in hilar cholangiocarcinoma. Endosc Int Open 2020; 8 (02) E203-E210 DOI: 10.1055/a-0990-9114.
• 628 Maeda T, Ebata T, Yokoyama Y. et al. Preoperative course of patients undergoing endoscopic nasobiliary drainage during the management of resectable perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2019; 26 (08) 341-347 DOI: 10.1002/jhbp.640?download=true.
• 629 Nakai Y, Yamamoto R, Matsuyama M. et al. Multicenter study of endoscopic preoperative biliary drainage for malignant hilar biliary obstruction: E-POD hilar study. J Gastroenterol Hepatol 2018; 33 (05) 1146-1153 DOI: 10.1111/jgh.14050?download=true.
• 630 Komaya K, Ebata T, Yokoyama Y. et al. Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage: A propensity score matching analysis of resectable perihilar cholangiocarcinoma. Surgery 2017; 161 (02) 394-404
• 631 Kim KM, Park JW, Lee JK. et al. A Comparison of Preoperative Biliary Drainage Methods for Perihilar Cholangiocarcinoma: Endoscopic versus Percutaneous Transhepatic Biliary Drainage. Gut Liver 2015; 9 (06) 791-799 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625710/pdf/gnl-09-791.pdf
• 632 Kennedy TJ, Yopp A, Qin Y. et al. Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB (Oxford) 2009; 11 (05) 445-451 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742615/pdf/hpb0011-0445.pdf
• 633 Miura S, Kanno A, Fukase K. et al. Preoperative biliary drainage of the hepatic lobe to be resected does not affect liver hypertrophy after percutaneous transhepatic portal vein embolization. Surg Endosc 2020; 34 (02) 667-674 DOI: 10.1007/s00464-019-06813-y.
• 634 Hintze RE, Abou-Rebyeh H, Adler A. et al. Magnetic resonance cholangiopancreatography-guided unilateral endoscopic stent placement for Klatskin tumors. Gastrointest Endosc 2001; 53 (01) 40-46
• 635 Abraham NS, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc 2002; 56 (06) 835-841
• 636 Paik WH, Park YS, Hwang JH. et al. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc 2009; 69 (01) 55-62
• 637 Saluja SS, Gulati M, Garg PK. et al. Endoscopic or percutaneous biliary drainage for gallbladder cancer: a randomized trial and quality of life assessment. Clin Gastroenterol Hepatol 2008; 6 (08) 944-950.e3 https://www.sciencedirect.com/science/article/abs/pii/S1542356508003418?via%3Dihub
• 638 Schima W, Prokesch R, Osterreicher C. et al. Biliary Wallstent endoprosthesis in malignant hilar obstruction: long-term results with regard to the type of obstruction. Clin Radiol 1997; 52 (03) 213-219
• 639 Rees J, Mytton J, Evison F. et al. The outcomes of biliary drainage by percutaneous transhepatic cholangiography for the palliation of malignant biliary obstruction in England between 2001 and 2014: a retrospective cohort study. BMJ Open 2020; 10 (01) e033576 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045186/pdf/bmjopen-2019-033576.pdf
• 640 Uberoi R, Das N, Moss J. et al. British Society of Interventional Radiology: Biliary Drainage and Stenting Registry (BDSR). Cardiovasc Intervent Radiol 2012; 35 (01) 127-138 DOI: 10.1007/s00270-011-0103-4.
• 641 Smith AC, Dowsett JF, Russell RC. et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344: 1655-1660
• 642 Speer AG, Cotton PB, Russell RC. et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2: 57-62
• 643 Almadi MA, Barkun A, Martel M. Plastic vs. Self-Expandable Metal Stents for Palliation in Malignant Biliary Obstruction: A Series of Meta-Analyses. Am J Gastroenterol 2017; 112 (02) 260-273
• 644 Lee TH, Moon JH, Choi JH. et al. Prospective comparison of endoscopic bilateral stent-in-stent versus stent-by-stent deployment for inoperable advanced malignant hilar biliary stricture. Gastrointest Endosc 2019; 90 (02) 222-230 https://www.sciencedirect.com/science/article/abs/pii/S0016510719301737?via%3Dihub
• 645 Sharaiha RZ, Kumta NA, Desai AP. et al. Endoscopic ultrasound-guided biliary drainage versus percutaneous transhepatic biliary drainage: predictors of successful outcome in patients who fail endoscopic retrograde cholangiopancreatography. Surg Endosc 2016; 30 (12) 5500-5505 DOI: 10.1007/s00464-016-4913-y.
• 646 Paik WH, Lee TH, Park DH. et al. EUS-Guided Biliary Drainage Versus ERCP for the Primary Palliation of Malignant Biliary Obstruction: A Multicenter Randomized Clinical Trial. Am J Gastroenterol 2018; 113 (07) 987-997
• 647 Bang JY, Navaneethan U, Hasan M. et al. Stent placement by EUS or ERCP for primary biliary decompression in pancreatic cancer: a randomized trial (with videos). Gastrointest Endosc 2018; 88 (01) 9-17
• 648 Dumonceau JM, Tringali A, Papanikolaou IS. et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline – Updated October 2017. Endoscopy 2018; 50 (09) 910-930 DOI: 10.1055/a-0659-9864.
• 649 Moole H, Dharmapuri S, Duvvuri A. et al. Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review. Can J Gastroenterol Hepatol 2016; 2016: 4726078 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014937/pdf/CJGH2016-4726078.pdf
• 650 Zhao XQ, Dong JH, Jiang K. et al. Comparison of percutaneous transhepatic biliary drainage and endoscopic biliary drainage in the management of malignant biliary tract obstruction: a meta-analysis. Dig Endosc 2015; 27 (01) 137-145 DOI: 10.1111/den.12320?download=true.
• 651 Born P, Rösch T, Triptrap A. et al. Long-term results of percutaneous transhepatic biliary drainage for benign and malignant bile duct strictures. Scand J Gastroenterol 1998; 33 (05) 544-549 DOI: 10.1080/00365529850172142?needAccess=true.
• 652 De Palma GD, Galloro G, Siciliano S. et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001; 53 (06) 547-553
• 653 Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 1998; 47 (05) 354-362
• 654 Bulajic M, Panic N, Radunovic M. et al. Clinical outcome in patients with hilar malignant strictures type II Bismuth-Corlette treated by minimally invasive unilateral versus bilateral endoscopic biliary drainage. Hepatobiliary Pancreat Dis Int 2012; 11 (02) 209-214
• 655 Cheng JL, Bruno MJ, Bergman JJ. et al. Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents. Gastrointest Endosc 2002; 56 (01) 33-39
• 656 Vienne A, Hobeika E, Gouya H. et al. Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment. Gastrointest Endosc 2010; 72 (04) 728-735
• 657 Harvey PR, Baldwin S, Mytton J. et al. Higher volume providers are associated with improved outcomes following ERCP for the palliation of malignant biliary obstruction. EClinicalMedicine 2020; 18: 100212 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948226/pdf/main.pdf
• 658 Tal AO, Vermehren J, Friedrich-Rust M. et al. Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction. World J Gastrointest Endosc 2014; 6 (01) 13-19 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921441/pdf/WJGE-6-13.pdf
• 659 Moole H, Tathireddy H, Dharmapuri S. et al. Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: A systematic review and meta-analysis. World J Gastroenterol 2017; 23 (07) 1278-1288 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323453/pdf/WJG-23-1278.pdf
• 660 Zoepf T, Jakobs R, Rosenbaum A. et al. Photodynamic therapy with 5-aminolevulinic acid is not effective in bile duct cancer. Gastrointest Endosc 2001; 54 (06) 763-766
• 661 Ortner ME, Caca K, Berr F. et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125 (05) 1355-1363 https://www.sciencedirect.com/science/article/abs/pii/S0016508503013623?via%3Dihub
• 662 Zoepf T, Jakobs R, Arnold JC. et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100 (11) 2426-2430
• 663 Pereira SP, Jitlal M, Duggan M. et al. PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer. ESMO Open 2018; 3 (05) e000379 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069917/pdf/esmoopen-2018-000379.pdf
• 664 Gonzalez-Carmona MA, Bolch M, Jansen C. et al. Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma. Aliment Pharmacol Ther 2019; 49 (04) 437-447 DOI: 10.1111/apt.15050?download=true.
• 665 Wentrup R, Winkelmann N, Mitroshkin A. et al. Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma. Gut Liver 2016; 10 (03) 470-475 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849702/pdf/gnl-10-470.pdf
• 666 Strand DS, Cosgrove ND, Patrie JT. et al. ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma. Gastrointest Endosc 2014; 80 (05) 794-804
• 667 Dolak W, Schwaighofer H, Hellmich B. et al. Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. United European Gastroenterol J 2017; 5 (01) 104-110 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384559/pdf/10.1177_2050640616654037.pdf
• 668 Kahaleh M, Mishra R, Shami VM. et al. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin Gastroenterol Hepatol 2008; 6 (03) 290-297 https://www.sciencedirect.com/science/article/abs/pii/S1542356507011469?via%3Dihub
• 669 Ben-Josef E, Normolle D, Ensminger WD. et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005; 23 (34) 8739-8747
• 670 Brunner TB, Blanck O, Lewitzki V. et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol 2019; 132: 42-47 https://www.sciencedirect.com/science/article/abs/pii/S0167814018336089?via%3Dihub
• 671 Tao R, Krishnan S, Bhosale PR. et al. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol 2016; 34 (03) 219-226 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980564/pdf/JCO613778.pdf
• 672 Lee J, Yoon WS, Koom WS. et al. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol 2019; 195 (02) 93-102 DOI: 10.1007/s00066-018-1367-2.
• 673 Frakulli R, Buwenge M, Macchia G. et al. Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review. Br J Radiol 2019; 92: 20180688 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580923/pdf/bjr.20180688.pdf
• 674 Barney BM, Olivier KR, Miller RC. et al. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 2012; 7: 67 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464963/pdf/1748-717X-7-67.pdf
• 675 Tse RV, Hawkins M, Lockwood G. et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26 (04) 657-664
• 676 Weiner AA, Olsen J, Ma D. et al. Stereotactic body radiotherapy for primary hepatic malignancies – Report of a phase I/II institutional study. Radiother Oncol 2016; 121 (01) 79-85 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543719/pdf/nihms872134.pdf
• 677 Kopek N, Holt MI, Hansen AT. et al. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010; 94 (01) 47-52
• 678 Schnapauff D, Denecke T, Grieser C. et al. Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2012; 35 (03) 581-587 DOI: 10.1007/s00270-011-0249-0.
• 679 Vogel A, Wege H, Caca K. et al. The diagnosis and treatment of cholangiocarcinoma. Dtsch Arztebl Int 2014; 111 (44) 748-754 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239580/pdf/Dtsch_Arztebl_Int-111-0748.pdf
• 680 Horgan AM, Amir E, Walter T. et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012; 30 (16) 1934-1940
• 681 Edeline J, Bonnetain F, Phelip JM. et al. Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. Journal of Clinical Oncology 2017; 35 (04) 225-225 DOI: 10.1200/JCO.2017.35.4_suppl.225.
• 682 Stein A, Arnold D, Bridgewater J. et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) – a randomized, multidisciplinary, multinational phase III trial. BMC Cancer 2015; 15: 564 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520064/pdf/12885_2015_Article_1498.pdf
• 683 Valle J, Wasan H, Palmer DH. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281 DOI: 10.1056/NEJMoa0908721?articleTools=true.
• 684 Shroff RT, Javle MM, Xiao L. et al. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol 2019; 5 (06) 824-830 https://jamanetwork.com/journals/jamaoncology/articlepdf/2730639/jamaoncology_shroff_2019_oi_190014.pdf
• 685 Markussen A, Jensen LH, Diness LV. et al. Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial. Cancers (Basel) 2020; 12 (07) 1975 https://pubmed.ncbi.nlm.nih.gov/32698410
• 686 Okusaka T, Nakachi K, Fukutomi A. et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103 (04) 469-474 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939781/pdf/6605779a.pdf
• 687 Valle JW, Furuse J, Jitlal M. et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014; 25 (02) 391-398
• 688 Park JO, Oh DY, Hsu C. et al. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat 2015; 47 (03) 343-361 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509359/pdf/crt-2014-308.pdf
• 689 Valle JW, Borbath I, Khan SA. et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl. 05) v28-v37 https://www.ncbi.nlm.nih.gov/pubmed/27664259
• 690 Abou-Alfa GK, Sahai V, Hollebecque A. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020; 21 (05) 671-684 https://pubmed.ncbi.nlm.nih.gov/32203698
• 691 Javle M, Roychowdhury S, Kelley RK. et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 2021; 6 (10) 803-815 https://pubmed.ncbi.nlm.nih.gov/34358484
• 692 Abou-Alfa GK, Sahai V, Hollebecque A. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. The Lancet Oncology 2020; 21 (05) 671-684
• 693 Subbiah V, Lassen U, Élez E. et al. Dabrafenib plus trametinib in patients with BRAF. Lancet Oncol 2020; 21 (09) 1234-1243 https://pubmed.ncbi.nlm.nih.gov/32818466
• 694 Javle M, Borad MJ, Azad NS. et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2021; 22 (09) 1290-1300 https://pubmed.ncbi.nlm.nih.gov/34339623
• 695 Cleary JM, Raghavan S, Wu Q. et al. None. Cancer Discov 2021; 11 (10) 2488-2505 https://pubmed.ncbi.nlm.nih.gov/33926920
• 696 Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol 2019; 16 (02) 105-122 https://pubmed.ncbi.nlm.nih.gov/30367139
• 697 Bahleda R, Meric-Bernstam F, Goyal L. et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol 2020; 31 (10) 1405-1412 https://pubmed.ncbi.nlm.nih.gov/32622884
• 698 Valle JW, Lamarca A, Goyal L. et al. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov 2017; 7 (09) 943-962 https://cancerdiscovery.aacrjournals.org/content/candisc/7/9/943.full.pdf
• 699 Marabelle A, Le Dung T, Ascierto PA. et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology 0 (00) JCO.19.02105 DOI: 10.1200/JCO.19.02105.
• 700 Le DT, Durham JN, Smith KN. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357: 409-413 https://science.sciencemag.org/content/sci/357/6349/409.full.pdf
• 701 Le DT, Uram JN, Wang H. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372 (26) 2509-2520 DOI: 10.1056/NEJMoa1500596?articleTools=true.
• 702 Goeppert B, Roessler S, Renner M. et al. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. Br J Cancer 2019; 120 (01) 109-114 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325153/pdf/41416_2018_Article_199.pdf
• 703 Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol 2018; DOI: 10.1038/s41571-018-0115-y. https://www.ncbi.nlm.nih.gov/pubmed/30367139
• 704 Jain A, Borad MJ, Kelley RK. et al. Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. JCO Precision Oncology 2018; 1-12 DOI: 10.1200/PO.17.00080.
• 705 Sia D, Losic B, Moeini A. et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun 2015; 6: 6087 https://air.unimi.it/retrieve/handle/2434/466290/761442/ncomms7087.pdf
• 706 Mazzaferro V, El-Rayes BF, Droz Dit Busset M. et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer 2019; 120 (02) 165-171 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342954/pdf/41416_2018_Article_334.pdf
• 707 Bahleda R, Italiano A, Hierro C. et al. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clin Cancer Res 2019; 25 (16) 4888-4897 https://clincancerres.aacrjournals.org/content/clincanres/25/16/4888.full.pdf
• 708 Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15 (12) 731-747 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419506/pdf/nihms-1016874.pdf
• 709 Solomon JP, Linkov I, Rosado A. et al. NTRK fusion detection across multiple assays and 33997 cases: diagnostic implications and pitfalls. Mod Pathol 2019; DOI: 10.1038/s41379-019-0324-7. https://www.ncbi.nlm.nih.gov/pubmed/31375766
• 710 Ross JS, Wang K, Gay L. et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014; 19 (03) 235-242 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958461/pdf/theoncologist_13352.pdf
• 711 Drilon A, Laetsch TW, Kummar S. et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378 (08) 731-739 DOI: 10.1056/NEJMoa1714448?articleTools=true.
• 712 Oh DY, Bang YJ. HER2-targeted therapies – a role beyond breast cancer. Nat Rev Clin Oncol 2019; DOI: 10.1038/s41571-019-0268-3. https://www.ncbi.nlm.nih.gov/pubmed/31548601
• 713 Neyaz A, Husain N, Gupta S. et al. Investigation of targetable predictive and prognostic markers in gallbladder carcinoma. J Gastrointest Oncol 2018; 9 (01) 111-125 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848045/pdf/jgo-09-01-111.pdf
• 714 Javle M, Churi C, Kang HC. et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol 2015; 8: 58 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469402/pdf/13045_2015_Article_155.pdf
• 715 Czink E, Heining C, Weber TF. et al. [Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer]. Z Gastroenterol 2016; 54 (05) 426-430 DOI: 10.1055/s-0042-103498.
• 716 Hyman DM, Puzanov I, Subbiah V. et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015; 373 (08) 726-736 DOI: 10.1056/NEJMoa1502309?articleTools=true.
• 717 Salama AKS, Li SL, Macrae ER. et al Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H. Journal of Clinical Oncology 2019; 37 (15) 3002-3002 , to, ISI>://WOS:000487345804592
• 718 Lavingia V, Fakih M. Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review. J Gastrointest Oncol 2016; 7 (06) E98-E102 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177579/pdf/jgo-07-06-E98.pdf
• 719 Kocsis J, Árokszállási A, András C. et al. Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion. J Gastrointest Oncol 2017; 8 (02) E32-E38 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401859/pdf/jgo-08-02-E32.pdf
• 720 Bunyatov T, Zhao A, Kovalenko J. et al. Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV. J Gastrointest Oncol 2019; 10 (04) 815-820 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657318/pdf/jgo-10-04-815.pdf
• 721 Abou-Alfa GK, Macarulla T, Javle MM. et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology 2020; 21 (06) 796-807
• 722 Lamarca A, Palmer DH, Wasan HS. et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021; 22 (05) 690-701 https://pubmed.ncbi.nlm.nih.gov/33798493
• 723 Zheng Y, Tu X, Zhao P. et al. A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin. Br J Cancer 2018; 119 (03) 291-295 https://pubmed.ncbi.nlm.nih.gov/29955136
• 724 Yoo C, Kim KP, Jeong JH. et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol 2021; DOI: 10.1016/S1470-2045(21)00486-1. https://pubmed.ncbi.nlm.nih.gov/34656226
• 725 Ramaswamy A, Ostwal V, Sharma A. et al. Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT). JAMA Oncol 2021; 7 (03) 436-439 https://pubmed.ncbi.nlm.nih.gov/33270098
• 726 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 2.1, 2017. http://www.leitlinienprogramm-onkologie.de/methodik/informationen-zur-methodik
• 727 Ashoori N, Bamberg F, Paprottka P. et al. Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation. Digestion 2012; 86 (04) 338-348
• 728 Boteon APCDs, Boteon YL, Vinuela EF. et al. The impact of transarterial chemoembolization induced complications on outcomes after liver transplantation: A propensity-matched study. Clin Transplant 2018; 32 (05) e13255
• 729 Habibollahi P, Shamchi SP, Choi JM. et al. Association of Complete Radiologic and Pathologic Response following Locoregional Therapy before Liver Transplantation with Long-Term Outcomes of Hepatocellular Carcinoma: A Retrospective Study. J Vasc Interv Radiol 2019; 30 (03) 323-329 https://www.sciencedirect.com/science/article/pii/S105104431831741X?via%3Dihub
• 730 Lu DS, Yu NC, Raman SS. et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41 (05) 1130-1137
• 731 Nicolini A, Martinetti L, Crespi S. et al. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21 (03) 327-332
• 732 Sandow T, Pavlus J, Field D. et al. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort. J Vasc Interv Radiol 2019; 30 (07) 995-1003
• 733 Tan CHN, Yu Y, Tan YRN. et al. Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere?. Ann Hepatobiliary Pancreat Surg 2018; 22 (01) 27-35
• 734 Werner JD, Frangakis C, Ruck JM. et al. Neoadjuvant Transarterial Chemoembolization Improves Survival After Liver Transplant in Patients With Hepatocellular Carcinoma. Exp Clin Transplant 2019; 17 (05) 638-643
• 735 Wang JH, Wang CC, Hung CH. et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 2012; 56 (02) 412-418 https://www.journal-of-hepatology.eu/article/S0168-8278(11)00524-1/fulltext
• 736 Peng ZW, Lin XJ, Zhang YJ. et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology 2012; 262 (03) 1022-1033
• 737 Hasegawa K, Kokudo N, Makuuchi M. et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013; 58 (04) 724-729 https://www.sciencedirect.com/science/article/pii/S016882781200877X?via%3Dihub
• 738 Fang Y, Chen W, Liang X. et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29 (01) 193-200 DOI: 10.1111/jgh.12441.
• 739 Miura JT, Johnston FM, Tsai S. et al. Surgical resection versus ablation for hepatocellular carcinoma ≤ 3 cm: a population-based analysis. HPB (Oxford) 2015; 17 (10) 896-901 https://www.hpbonline.org/article/S1365-182X(15)31122-9/pdf
• 740 Zhang M, Ma H, Zhang J. et al. Comparison of microwave ablation and hepatic resection for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther 2017; 10: 4829-4839 https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1608315791_5fdcf38f6a57c/OTT-141968-comparison-of-microwave-ablation-and-hepatic-resection-for-h_100317.pdf
• 741 Zhang QB, Zhang XG, Jiang RD. et al. Microwave ablation versus hepatic resection for the treatment of hepatocellular carcinoma and oesophageal variceal bleeding in cirrhotic patients. Int J Hyperthermia 2017; 33 (03) 255-262 DOI: 10.1080/02656736.2016.1257824?needAccess=true.
• 742 Liu PH, Hsu CY, Hsia CY. et al. Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2  cm in a Propensity Score Model. Ann Surg 2016; 263 (03) 538-545 https://www.ingentaconnect.com/content/wk/sla/2016/00000263/00000003/art00040;jsessionid=1n53m5b4ljd7b.x-ic-live-01
• 743 Takayasu K, Arii S, Sakamoto M. et al. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting. Liver Int 2018; 38 (03) 484-493 DOI: 10.1111/liv.13670.
• 744 Hung HH, Chiou YY, Hsia CY. et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol 2011; 9 (01) 79-86 https://www.cghjournal.org/article/S1542-3565(10)00847-5/pdf
• 745 Ogihara M, Wong LL, Machi J. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. HPB (Oxford) 2005; 7 (03) 214-221
• 746 Lü MD, Kuang M, Liang LJ. et al. [Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial]. Zhonghua Yi Xue Za Zhi 2006; 86 (12) 801-805
• 747 Lupo L, Panzera P, Giannelli G. et al. Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection?. HPB (Oxford) 2007; 9 (06) 429-434
• 748 Abu-Hilal M, Primrose JN, Casaril A. et al. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg 2008; 12 (09) 1521-1526
• 749 Tashiro H, Aikata H, Waki K. et al. Treatment strategy for early hepatocellular carcinomas: comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection. J Surg Oncol 2011; 104 (01) 3-9
• 750 Kim JW, Shin SS, Kim JK. et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection. Korean J Radiol 2013; 14 (04) 626-635
• 751 Tang C, Shen J, Feng W. et al. Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Medicine (Baltimore) 2016; 95 (20) e3754 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902444/pdf/medi-95-e3754.pdf
• 752 Bholee AK, Peng K, Zhou Z. et al. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. Clin Transl Oncol 2017; 19 (07) 844-852
• 753 Pan T, Mu LW, Wu C. et al. Comparison of Combined Transcatheter Arterial Chemoembolization and CT-guided Radiofrequency Ablation with Surgical Resection in Patients with Hepatocellular Carcinoma within the Up-to-seven Criteria: A Multicenter Case-matched Study. J Cancer 2017; 8 (17) 3506-3513 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687165/pdf/jcav08p3506.pdf
• 754 Zhang R, Shen L, Zhao L. et al. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol 2018; 24 (04) 219-224 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045511/pdf/dir-24-4-219.pdf
• 755 Lin DY, Liaw YF, Lee TY. et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma – a randomized controlled trial. Gastroenterology 1988; 94 (02) 453-456 https://www.sciencedirect.com/science/article/abs/pii/0016508588904362?via%3Dihub
• 756 Pelletier G, Roche A, Ink O. et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11 (02) 181-184
• 757 A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332 (19) 1256-1261 DOI: 10.1056/NEJM199505113321903?articleTools=true.
• 758 Bruix J, Llovet JM, Castells A. et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27 (06) 1578-1583 DOI: 10.1002/hep.510270617?download=true.
• 759 Pelletier G, Ducreux M, Gay F. et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29 (01) 129-134
• 760 Stefanini GF, Amorati P, Biselli M. et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 1995; 75 (10) 2427-2434 https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2819950515%2975%3A10%3C2427%3A%3AAID-CNCR2820751007%3E3.0.CO%3B2-J?download=true
• 761 Bronowicki JP, Vetter D, Dumas F. et al. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 1994; 74 (01) 16-24 DOI: 10.1002/1097-0142%2819940701%2974%3A1%3C16%3A%3AAID-CNCR2820740105%3E3.0.CO%3B2-V?download=true.
• 762 Kim JH, Yoon HK, Kim SY. et al. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther 2009; 29 (12) 1291-1298 DOI: 10.1111/j.1365-2036.2009.04016.x?download=true.
• 763 Herber S, Otto G, Schneider J. et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2007; 30 (06) 1156-1165 DOI: 10.1007/s00270-007-9032-7.
• 764 Chung GE, Lee JH, Kim HY. et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011; 258 (02) 627-634
• 765 Georgiades CS, Hong K, D‘Angelo M. et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16 (12) 1653-1659 https://www.sciencedirect.com/science/article/pii/S1051044307607933?via%3Dihub
• 766 Okazaki M, Higashihara H, Koganemaru HE. et al. Transcatheter arterial embolization for inoperable hepatocellular carcinoma. Jpn J Clin Radiol 1991; 36: 535-539
• 767 Sacco R, Bargellini I, Bertini M. et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22 (11) 1545-1552
• 768 van Malenstein H, Maleux G, Vandecaveye V. et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34 (07) 368-376 https://www.karger.com/Article/Pdf/329602
• 769 Dhanasekaran R, Kooby DA, Staley CA. et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101 (06) 476-480 DOI: 10.1002/jso.21522?download=true.
• 770 Ferrer Puchol MD, la Parra C, Esteban E. et al. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. Radiologia 2011; 53 (03) 246-253 https://www.sciencedirect.com/science/article/abs/pii/S0033833810003449?via%3Dihub
• 771 Wiggermann P, Sieron D, Brosche C. et al. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit 2011; 17 (04) Cr189-Cr195 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539521/pdf/medscimonit-17-4-cr189.pdf
• 772 Song MJ, Chun HJ, Song DS. et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57 (06) 1244-1250
• 773 Megías Vericat JE, García Marcos R, López Briz E. et al. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. Radiologia 2015; 57 (06) 496-504 https://www.sciencedirect.com/science/article/abs/pii/S0033833815000764?via%3Dihub
• 774 Kloeckner R, Weinmann A, Prinz F. et al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 2015; 15: 465 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460638/pdf/12885_2015_Article_1480.pdf
• 775 Facciorusso A, Mariani L, Sposito C. et al. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 2016; 31 (03) 645-653 DOI: 10.1111/jgh.13147?download=true.
• 776 Baur J, Ritter CO, Germer CT. et al. Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma. Hepat Med 2016; 8: 69-74 https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1615551010_604b5a224c25d/HMER-105395-transarterial-chemoembolization--tace--with-drug-eluting-bea_062016.pdf
• 777 Gao S, Yang Z, Zheng Z. et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013; 60 (124) 813-820
• 778 Huang K, Zhou Q, Wang R. et al. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29 (05) 920-925 DOI: 10.1111/jgh.12439?download=true.
• 779 Zhou X, Tang Z, Wang J. et al. Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis. Int J Clin Exp Med 2014; 7 (11) 3892-3903
• 780 Zou JH, Zhang L, Ren ZG. et al. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis 2016; 17 (08) 510-517 DOI: 10.1111/1751-2980.12380?download=true.
• 781 Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Dig Liver Dis 2016; 48 (06) 571-577
• 782 Celotti A, Solaini L, Montori G. et al. Preoperative biliary drainage in hilar cholangiocarcinoma: Systematic review and meta-analysis. Eur J Surg Oncol 2017; 43 (09) 1628-1635
• 783 Ramanathan R, Borrebach J, Tohme S. et al. Preoperative Biliary Drainage Is Associated with Increased Complications After Liver Resection for Proximal Cholangiocarcinoma. J Gastrointest Surg 2018; 22 (11) 1950-1957 DOI: 10.1007/s11605-018-3861-3.
• 784 Cai Y, Tang Q, Xiong X. et al. Preoperative biliary drainage versus direct surgery for perihilar cholangiocarcinoma: A retrospective study at a single center. Biosci Trends 2017; 11 (03) 319-325 https://www.jstage.jst.go.jp/article/bst/11/3/11_2017.01107/_pdf
• 785 Farges O, Regimbeau JM, Fuks D. et al. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 2013; 100 (02) 274-283 DOI: 10.1002/bjs.8950?download=true.
• 786 Xiong JJ, Nunes QM, Huang W. et al. Preoperative biliary drainage in patients with hilar cholangiocarcinoma undergoing major hepatectomy. World J Gastroenterol 2013; 19 (46) 8731-8739 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870521/pdf/WJG-19-8731.pdf
• 787 Wang L, Lin N, Xin F. et al. A systematic review of the comparison of the incidence of seeding metastasis between endoscopic biliary drainage and percutaneous transhepatic biliary drainage for resectable malignant biliary obstruction. World J Surg Oncol 2019; 17 (01) 116 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612106/pdf/12957_2019_Article_1656.pdf
• 788 Kishi Y, Shimada K, Nara S. et al. The type of preoperative biliary drainage predicts short-term outcome after major hepatectomy. Langenbecks Arch Surg 2016; 401 (04) 503-511 DOI: 10.1007/s00423-016-1427-y.
• 789 Sangchan A, Kongkasame W, Pugkhem A. et al. Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial. Gastrointest Endosc 2012; 76 (01) 93-99